Beyond the Bolus - Diabetes Technology Education for Healthcare Providers https://www.omnipod.com/hcp/clinical-resources/podcast en Copyright 2024 Insulet, Maker of Omnipod Brought to you by the makers of Omnipod, Beyond the Bolus explores topics beyond the basics of diabetes management and takes a closer look at the treatment and care of diabetes through the unique perspectives and great minds of people within the diabetes community. Hosted by Dena Gottesman MS, RD, CDCES and Nancy Hanna RN, BSN, CDE, this dynamic duo brings forth their passion for serving patients with diabetes and their curiosity to learn to the series. The episodes will include conversations on visions for the future of diabetes care and technology, practical tips for building a care team, compelling clinical data and more! https://megaphone.imgix.net/podcasts/62144cae-276f-11f1-9085-675f30d76444/image/65a01a5e4565825105db2ce2af5a7556.png?ixlib=rails-4.3.1&max-w=3000&max-h=3000&fit=crop&auto=format,compress Beyond the Bolus - Diabetes Technology Education for Healthcare Providers https://www.omnipod.com/hcp/clinical-resources/podcast no episodic Insulet, Maker of Omnipod Brought to you by the makers of Omnipod, Beyond the Bolus explores topics beyond the basics of diabetes management and takes a closer look at the treatment and care of diabetes through the unique perspectives and great minds of people within the diabetes community. Hosted by Dena Gottesman MS, RD, CDCES and Nancy Hanna RN, BSN, CDE, this dynamic duo brings forth their passion for serving patients with diabetes and their curiosity to learn to the series. The episodes will include conversations on visions for the future of diabetes care and technology, practical tips for building a care team, compelling clinical data and more! Brought to you by the makers of Omnipod, Beyond the Bolus explores topics beyond the basics of diabetes management and takes a closer look at the treatment and care of diabetes through the unique perspectives and great minds of people within the diabetes community.


Hosted by Dena Gottesman MS, RD, CDCES and Nancy Hanna RN, BSN, CDE, this dynamic duo brings forth their passion for serving patients with diabetes and their curiosity to learn to the series. The episodes will include conversations on visions for the future of diabetes care and technology, practical tips for building a care team, compelling clinical data and more!

]]> Insulet, Maker of Omnipod dan@thepodcastguys.co.uk Tubeless Trendsetters: The Freedom Factor of Omnipod® 5 with Dr. David Ahn and Justin Eastzer This month’s episode brings together two voices from different sides of diabetes care: Dr. David Ahn, endocrinologist and Chief of Diabetes Services at Hoag Hospital's Mary and Dick Allen Diabetes Centre in Newport Beach, California, and Justin Eastzer, diabetes advocate known as @diabetech. Together with host Nancy Hanna, they dig into what going tubeless means for the people wearing it and the clinicians prescribing it.   Dr. Ahn shares how the absence of tubing helps patients overcome hesitation around starting pump therapy, particularly those concerned about visibility and medical stigma. He discusses the clinical impact of not needing to disconnect for daily activities*, including his personal experience of seeing how this can help reduce rebound hyperglycemia, and he also highlights how the simplicity of Omnipod 5 has been transformative for his older patient population. Justin offers a firsthand patient perspective on how the tubeless form factor gives him freedom across every area of daily life, from workouts to travel, getting dressed, without ever needing to think about where his pump is.   The conversation also covers the expanded site rotation options that come with a tubeless system, the convenience of the automated cannula insertion for those with needle phobia, and the latest Omnipod 5 software update featuring the lower 100 mg/dL Target Glucose setting. Dr. Ahn closes with how the free 30-day sample kit†† and single-prescription simplicity help clinicians get hesitant patients started.   Whether you're a clinician, educator, or someone living with diabetes, this episode offers a compelling look at how removing tubing removes barriers to better outcomes. ---------- ·       00:00 - Why tubeless matters: reducing stigma and starting AID ·       05:06 - The patient perspective: freedom in daily life ·       08:57 - Site rotation, waterproof form-factor†, and not needing to disconnect for daily activities* ·       11:41 - Automated insertion and simplicity for all ages ·       16:50 - Getting patients started with a single prescription for Omnipod 5 ---------- * The Pod has an IP28 rating for up to 25 feet for 60 minutes. The Omnipod 5 Controller is not waterproof. † Daily normal activities are related to recreational, educational, and occupational activities. The Pod must be removed before Magnetic Resonance Imaging (MRI), Computed Tomography (CT) scan, or diathermy treatment, and the Controller or smartphone should be placed outside of the procedure room. Refer to the Omnipod® 5 Automated Insulin Delivery System User Guide. †† Omnipod® 5 Intro Kit 30-Day Trial  Terms and Conditions 1. Program Eligibility Eligibility criteria: Subject to program limitations and terms and conditions, the Omnipod 5 Intro Kit 30-day trial program (the “Program”) is open to patients who have a valid Omnipod 5 prescription as well as a compatible CGM prescription and who have commercial or private insurance, including plans available through state and federal healthcare exchanges. In order to be eligible, the patient’s eligible insurance plan must include coverage for Omnipod 5 Pods. The Program is open to new Pod Therapy patients coming from multiple daily injections or tubed pumps only who have not previously used Omnipod 5, Omnipod DASH® or Omnipod Insulin Management System. This offer is not valid for participants whose Omnipod 5 or compatible CGM prescription is paid for in whole or in part by Medicare, Medicaid, or any other federal or state programs. It is not valid for cash-paying participants or where prohibited by law. A participant is considered cash-paying where the participant has no insurance coverage for Omnipod 5 or where the participant has commercial or private insurance but Insulet determines in its sole discretion the participant is effectively uninsured because such coverage does not provide a material level of financial assistance for the cost of an Omnipod 5 prescription. Participants on certain commercial insurance plans may not be eligible. This offer is only valid in the United States, Puerto Rico, and the U.S. territories. Participants receiving their products through the Durable Medical Equipment or Pharmacy Durable Medical Equipment channel are not eligible to participate in the copay card program. Please contact Insulet Customer Support at 1-800-591-3455 for details. 2. Program Details With this program, Participants may be eligible to receive a limited supply of Omnipod 5 products at no cost for them. Eligible participants have two (2) options, based on the following: • A participant shall sign the Omnipod® 5 Intro Kit 30-Day Trial Acknowledgement through the appropriate platform provided by Insulet. • Once Insulet has received the request, the request shall be escalated to Insulet’s pharmacy partner, where a request for a prescription shall be sent to the participant’s healthcare professional. If a valid prescription is received, both for the Omnipod 5 Intro Kit and the Omnipod 5 Pods, the participant’s benefits will be checked by Insulet or its partners.    • IF the benefits check results in a monthly copay equal to or below two hundred dollars ($200), then Insulet shall issue a one-time only copay card to the participant, for a value equal to the out-of-pocket expenses the participant would have to pay for an Omnipod 5 Intro Kit, in accordance with Section 3, below.    • IF the benefits check result in a copay greater than two hundred dollars ($200), Insulet, or its authorized partners, shall arrange for the shipment of one (1) Omnipod 5 Intro Kit, in accordance with Section 4, below.    • For the purpose of clarity, the term “copay” shall encompass any out-of-pocket expense for one (1) month’s supply of Pods, including any deductible, copays and other out-of-pocket expenses that the participant would have to disburse to procure said supply of Pods.    • Any copay assistance may not apply to a participant’s health plan’s deductible if prohibited by state law or by a health plan.    • In order to use the Omnipod 5 System in Automated Mode, the User must also procure a compatible CGM. This program does not include supply of a compatible CGM. Insulet reserves the right to change, amend or rescind this Program, in whole or in part, at any time. 3. Copay Card Should participant be deemed eligible to receive an Omnipod 5 Copay Card, participant shall receive electronically one (1) Omnipod 5 Copay Card, valid for a single use, in the amount required for the participant to procure one (1) Omnipod 5 Intro Kit, which shall include: • One (1) Omnipod 5 Controller • Ten (10) Omnipod 5 Pods • One (1) Omnipod 5 User Guide • One (1) Controller charging cable 4. Product Dispense Should participant be deemed eligible to receive a one-time dispense of Omnipod 5 Pods at no cost to them, Insulet, or its authorized partner, shall dispense one (1) Omnipod 5 Intro Kit, which shall include: • One (1) Omnipod 5 Controller • Ten (10) Omnipod 5 Pods • One (1) Omnipod 5 User Guide • One (1) Controller charging cable The Omnipod 5 Intro Kit shall be delivered to the shipping address indicated by participant in their Acknowledgment Form. Any estimate date of delivery is given solely for participant’s information and does not constitute a warranty that the Intro Kit will be delivered on said date. Participant is responsible to provide an accurate delivery address, to receive shipment of the Intro Kit and to verify the content of the Intro Kit.   How do medical devices like Omnipod 5 improve the lives of people living with diabetes? How can Healthcare Professionals implement Omnipod 5 Automated Insulin Delivery (AID) Systems in practice?   Beyond the Bolus is a US-based diabetes education podcast for healthcare professionals who treat patients living with type 1 (T1D) and type 2 diabetes (T2D).   Hosted by Insulet's Clinical Services Managers, Nancy Hanna RN, BSN, CDE, and Dena Gottesman MS, RD, CDCES, this dynamic duo care deeply about helping healthcare professionals (HCP)'s and patients simplify life with diabetes. Episodes cover a range of topics such as, how to get started with Omnipod 5 to ongoing care management, helping HCPs make patient conversations more efficient and effective.   Beyond the Bolus also dives into the latest clinical research and data with prominent diabetes experts from across the globe who share real-world experiences and offer insights into what the future of diabetes care could look like with devices like Omnipod 5.   If you're looking to empower your patients to take back control of their diabetes, then this is the podcast for you.   INS-OHS-07-2026-00089V1.0 Wed, 09 Sep 2026 11:30:00 -0000 full Insulet, Maker of Omnipod This month’s episode brings together two voices from different sides of diabetes care: Dr. David Ahn, endocrinologist and Chief of Diabetes Services at Hoag Hospital's Mary and Dick Allen Diabetes Centre in Newport Beach, California, and Justin Eastzer, diabetes advocate known as @diabetech. Together with host Nancy Hanna, they dig into what going tubeless means for the people wearing it and the clinicians prescribing it.   Dr. Ahn shares how the absence of tubing helps patients overcome hesitation around starting pump therapy, particularly those concerned about visibility and medical stigma. He discusses the clinical impact of not needing to disconnect for daily activities*, including his personal experience of seeing how this can help reduce rebound hyperglycemia, and he also highlights how the simplicity of Omnipod 5 has been transformative for his older patient population. Justin offers a firsthand patient perspective on how the tubeless form factor gives him freedom across every area of daily life, from workouts to travel, getting dressed, without ever needing to think about where his pump is.   The conversation also covers the expanded site rotation options that come with a tubeless system, the convenience of the automated cannula insertion for those with needle phobia, and the latest Omnipod 5 software update featuring the lower 100 mg/dL Target Glucose setting. Dr. Ahn closes with how the free 30-day sample kit†† and single-prescription simplicity help clinicians get hesitant patients started.   Whether you're a clinician, educator, or someone living with diabetes, this episode offers a compelling look at how removing tubing removes barriers to better outcomes. ---------- ·       00:00 - Why tubeless matters: reducing stigma and starting AID ·       05:06 - The patient perspective: freedom in daily life ·       08:57 - Site rotation, waterproof form-factor†, and not needing to disconnect for daily activities* ·       11:41 - Automated insertion and simplicity for all ages ·       16:50 - Getting patients started with a single prescription for Omnipod 5 ---------- * The Pod has an IP28 rating for up to 25 feet for 60 minutes. The Omnipod 5 Controller is not waterproof. † Daily normal activities are related to recreational, educational, and occupational activities. The Pod must be removed before Magnetic Resonance Imaging (MRI), Computed Tomography (CT) scan, or diathermy treatment, and the Controller or smartphone should be placed outside of the procedure room. Refer to the Omnipod® 5 Automated Insulin Delivery System User Guide. †† Omnipod® 5 Intro Kit 30-Day Trial  Terms and Conditions 1. Program Eligibility Eligibility criteria: Subject to program limitations and terms and conditions, the Omnipod 5 Intro Kit 30-day trial program (the “Program”) is open to patients who have a valid Omnipod 5 prescription as well as a compatible CGM prescription and who have commercial or private insurance, including plans available through state and federal healthcare exchanges. In order to be eligible, the patient’s eligible insurance plan must include coverage for Omnipod 5 Pods. The Program is open to new Pod Therapy patients coming from multiple daily injections or tubed pumps only who have not previously used Omnipod 5, Omnipod DASH® or Omnipod Insulin Management System. This offer is not valid for participants whose Omnipod 5 or compatible CGM prescription is paid for in whole or in part by Medicare, Medicaid, or any other federal or state programs. It is not valid for cash-paying participants or where prohibited by law. A participant is considered cash-paying where the participant has no insurance coverage for Omnipod 5 or where the participant has commercial or private insurance but Insulet determines in its sole discretion the participant is effectively uninsured because such coverage does not provide a material level of financial assistance for the cost of an Omnipod 5 prescription. Participants on certain commercial insurance plans may not be eligible. This offer is only valid in the United States, Puerto Rico, and the U.S. territories. Participants receiving their products through the Durable Medical Equipment or Pharmacy Durable Medical Equipment channel are not eligible to participate in the copay card program. Please contact Insulet Customer Support at 1-800-591-3455 for details. 2. Program Details With this program, Participants may be eligible to receive a limited supply of Omnipod 5 products at no cost for them. Eligible participants have two (2) options, based on the following: • A participant shall sign the Omnipod® 5 Intro Kit 30-Day Trial Acknowledgement through the appropriate platform provided by Insulet. • Once Insulet has received the request, the request shall be escalated to Insulet’s pharmacy partner, where a request for a prescription shall be sent to the participant’s healthcare professional. If a valid prescription is received, both for the Omnipod 5 Intro Kit and the Omnipod 5 Pods, the participant’s benefits will be checked by Insulet or its partners.    • IF the benefits check results in a monthly copay equal to or below two hundred dollars ($200), then Insulet shall issue a one-time only copay card to the participant, for a value equal to the out-of-pocket expenses the participant would have to pay for an Omnipod 5 Intro Kit, in accordance with Section 3, below.    • IF the benefits check result in a copay greater than two hundred dollars ($200), Insulet, or its authorized partners, shall arrange for the shipment of one (1) Omnipod 5 Intro Kit, in accordance with Section 4, below.    • For the purpose of clarity, the term “copay” shall encompass any out-of-pocket expense for one (1) month’s supply of Pods, including any deductible, copays and other out-of-pocket expenses that the participant would have to disburse to procure said supply of Pods.    • Any copay assistance may not apply to a participant’s health plan’s deductible if prohibited by state law or by a health plan.    • In order to use the Omnipod 5 System in Automated Mode, the User must also procure a compatible CGM. This program does not include supply of a compatible CGM. Insulet reserves the right to change, amend or rescind this Program, in whole or in part, at any time. 3. Copay Card Should participant be deemed eligible to receive an Omnipod 5 Copay Card, participant shall receive electronically one (1) Omnipod 5 Copay Card, valid for a single use, in the amount required for the participant to procure one (1) Omnipod 5 Intro Kit, which shall include: • One (1) Omnipod 5 Controller • Ten (10) Omnipod 5 Pods • One (1) Omnipod 5 User Guide • One (1) Controller charging cable 4. Product Dispense Should participant be deemed eligible to receive a one-time dispense of Omnipod 5 Pods at no cost to them, Insulet, or its authorized partner, shall dispense one (1) Omnipod 5 Intro Kit, which shall include: • One (1) Omnipod 5 Controller • Ten (10) Omnipod 5 Pods • One (1) Omnipod 5 User Guide • One (1) Controller charging cable The Omnipod 5 Intro Kit shall be delivered to the shipping address indicated by participant in their Acknowledgment Form. Any estimate date of delivery is given solely for participant’s information and does not constitute a warranty that the Intro Kit will be delivered on said date. Participant is responsible to provide an accurate delivery address, to receive shipment of the Intro Kit and to verify the content of the Intro Kit.   How do medical devices like Omnipod 5 improve the lives of people living with diabetes? How can Healthcare Professionals implement Omnipod 5 Automated Insulin Delivery (AID) Systems in practice?   Beyond the Bolus is a US-based diabetes education podcast for healthcare professionals who treat patients living with type 1 (T1D) and type 2 diabetes (T2D).   Hosted by Insulet's Clinical Services Managers, Nancy Hanna RN, BSN, CDE, and Dena Gottesman MS, RD, CDCES, this dynamic duo care deeply about helping healthcare professionals (HCP)'s and patients simplify life with diabetes. Episodes cover a range of topics such as, how to get started with Omnipod 5 to ongoing care management, helping HCPs make patient conversations more efficient and effective.   Beyond the Bolus also dives into the latest clinical research and data with prominent diabetes experts from across the globe who share real-world experiences and offer insights into what the future of diabetes care could look like with devices like Omnipod 5.   If you're looking to empower your patients to take back control of their diabetes, then this is the podcast for you.   INS-OHS-07-2026-00089V1.0 This month’s episode brings together two voices from different sides of diabetes care: Dr. David Ahn, endocrinologist and Chief of Diabetes Services at Hoag Hospital's Mary and Dick Allen Diabetes Centre in Newport Beach, California, and Justin Eastzer, diabetes advocate known as @diabetech. Together with host Nancy Hanna, they dig into what going tubeless means for the people wearing it and the clinicians prescribing it.

 

Dr. Ahn shares how the absence of tubing helps patients overcome hesitation around starting pump therapy, particularly those concerned about visibility and medical stigma. He discusses the clinical impact of not needing to disconnect for daily activities*, including his personal experience of seeing how this can help reduce rebound hyperglycemia, and he also highlights how the simplicity of Omnipod 5 has been transformative for his older patient population. Justin offers a firsthand patient perspective on how the tubeless form factor gives him freedom across every area of daily life, from workouts to travel, getting dressed, without ever needing to think about where his pump is.

 

The conversation also covers the expanded site rotation options that come with a tubeless system, the convenience of the automated cannula insertion for those with needle phobia, and the latest Omnipod 5 software update featuring the lower 100 mg/dL Target Glucose setting. Dr. Ahn closes with how the free 30-day sample kit†† and single-prescription simplicity help clinicians get hesitant patients started.

 

Whether you're a clinician, educator, or someone living with diabetes, this episode offers a compelling look at how removing tubing removes barriers to better outcomes.

----------

·       00:00 - Why tubeless matters: reducing stigma and starting AID

·       05:06 - The patient perspective: freedom in daily life

·       08:57 - Site rotation, waterproof form-factor†, and not needing to disconnect for daily activities*

·       11:41 - Automated insertion and simplicity for all ages

·       16:50 - Getting patients started with a single prescription for Omnipod 5

----------

* The Pod has an IP28 rating for up to 25 feet for 60 minutes. The Omnipod 5 Controller is not waterproof.

† Daily normal activities are related to recreational, educational, and occupational activities. The Pod must be removed before Magnetic Resonance Imaging (MRI), Computed Tomography (CT) scan, or diathermy treatment, and the Controller or smartphone should be placed outside of the procedure room. Refer to the Omnipod® 5 Automated Insulin Delivery System User Guide.

†† Omnipod® 5 Intro Kit 30-Day Trial 
Terms and Conditions

1. Program Eligibility

Eligibility criteria: Subject to program limitations and terms and conditions, the Omnipod 5 Intro Kit 30-day trial program (the “Program”) is open to patients who have a valid Omnipod 5 prescription as well as a compatible CGM prescription and who have commercial or private insurance, including plans available through state and federal healthcare exchanges. In order to be eligible, the patient’s eligible insurance plan must include coverage for Omnipod 5 Pods. The Program is open to new Pod Therapy patients coming from multiple daily injections or tubed pumps only who have not previously used Omnipod 5, Omnipod DASH® or Omnipod Insulin Management System.

This offer is not valid for participants whose Omnipod 5 or compatible CGM prescription is paid for in whole or in part by Medicare, Medicaid, or any other federal or state programs. It is not valid for cash-paying participants or where prohibited by law. A participant is considered cash-paying where the participant has no insurance coverage for Omnipod 5 or where the participant has commercial or private insurance but Insulet determines in its sole discretion the participant is effectively uninsured because such coverage does not provide a material level of financial assistance for the cost of an Omnipod 5 prescription. Participants on certain commercial insurance plans may not be eligible. This offer is only valid in the United States, Puerto Rico, and the U.S. territories. Participants receiving their products through the Durable Medical Equipment or Pharmacy Durable Medical Equipment channel are not eligible to participate in the copay card program.

Please contact Insulet Customer Support at 1-800-591-3455 for details.

2. Program Details

With this program, Participants may be eligible to receive a limited supply of Omnipod 5 products at no cost for them. Eligible participants have two (2) options, based on the following:

• A participant shall sign the Omnipod® 5 Intro Kit 30-Day Trial Acknowledgement through the appropriate platform provided by Insulet.

• Once Insulet has received the request, the request shall be escalated to Insulet’s pharmacy partner, where a request for a prescription shall be sent to the participant’s healthcare professional. If a valid prescription is received, both for the Omnipod 5 Intro Kit and the Omnipod 5 Pods, the participant’s benefits will be checked by Insulet or its partners.

   • IF the benefits check results in a monthly copay equal to or below two hundred dollars ($200), then Insulet shall issue a one-time only copay card to the participant, for a value equal to the out-of-pocket expenses the participant would have to pay for an Omnipod 5 Intro Kit, in accordance with Section 3, below.

   • IF the benefits check result in a copay greater than two hundred dollars ($200), Insulet, or its authorized partners, shall arrange for the shipment of one (1) Omnipod 5 Intro Kit, in accordance with Section 4, below.

   • For the purpose of clarity, the term “copay” shall encompass any out-of-pocket expense for one (1) month’s supply of Pods, including any deductible, copays and other out-of-pocket expenses that the participant would have to disburse to procure said supply of Pods.

   • Any copay assistance may not apply to a participant’s health plan’s deductible if prohibited by state law or by a health plan.

   • In order to use the Omnipod 5 System in Automated Mode, the User must also procure a compatible CGM. This program does not include supply of a compatible CGM.

Insulet reserves the right to change, amend or rescind this Program, in whole or in part, at any time.

3. Copay Card

Should participant be deemed eligible to receive an Omnipod 5 Copay Card, participant shall receive electronically one (1) Omnipod 5 Copay Card, valid for a single use, in the amount required for the participant to procure one (1) Omnipod 5 Intro Kit, which shall include:

• One (1) Omnipod 5 Controller
• Ten (10) Omnipod 5 Pods
• One (1) Omnipod 5 User Guide
• One (1) Controller charging cable

4. Product Dispense

Should participant be deemed eligible to receive a one-time dispense of Omnipod 5 Pods at no cost to them, Insulet, or its authorized partner, shall dispense one (1) Omnipod 5 Intro Kit, which shall include:

• One (1) Omnipod 5 Controller
• Ten (10) Omnipod 5 Pods
• One (1) Omnipod 5 User Guide
• One (1) Controller charging cable

The Omnipod 5 Intro Kit shall be delivered to the shipping address indicated by participant in their Acknowledgment Form. Any estimate date of delivery is given solely for participant’s information and does not constitute a warranty that the Intro Kit will be delivered on said date. Participant is responsible to provide an accurate delivery address, to receive shipment of the Intro Kit and to verify the content of the Intro Kit.

 

How do medical devices like Omnipod 5 improve the lives of people living with diabetes? How can Healthcare Professionals implement Omnipod 5 Automated Insulin Delivery (AID) Systems in practice?

 

Beyond the Bolus is a US-based diabetes education podcast for healthcare professionals who treat patients living with type 1 (T1D) and type 2 diabetes (T2D).

 

Hosted by Insulet's Clinical Services Managers, Nancy Hanna RN, BSN, CDE, and Dena Gottesman MS, RD, CDCES, this dynamic duo care deeply about helping healthcare professionals (HCP)'s and patients simplify life with diabetes. Episodes cover a range of topics such as, how to get started with Omnipod 5 to ongoing care management, helping HCPs make patient conversations more efficient and effective.

 

Beyond the Bolus also dives into the latest clinical research and data with prominent diabetes experts from across the globe who share real-world experiences and offer insights into what the future of diabetes care could look like with devices like Omnipod 5.

 

If you're looking to empower your patients to take back control of their diabetes, then this is the podcast for you.

 

INS-OHS-07-2026-00089V1.0

]]> 1187 Settings, Trust, and Time in Range: Optimizing Omnipod® 5 with Dr. Sufyan Hussain Recorded live at the ADA Scientific Sessions New Orleans, Nancy Hanna sits down with Dr. Sufyan Hussain, Consultant Physician in Diabetes and Endocrinology at Guy's and St Thomas' NHS Foundation Trust and Honorary Academic at King's College London, to explore why real-world evidence matters as much as clinical trial data.  Dr. Hussain shares how real-world data helped secure widescale public funding for automated insulin delivery (AID) systems in the UK, and walks through practical, evidence-based recommendations for healthcare providers: using stronger Target Glucose, Insulin-to-Carb ratio (≤350/TDI) and Correction Factor (≤1500/TDI) settings1. He also discusses the importance of an independent, validated comparator like lab-based A1C when evaluating outcomes across systems.  The conversation also covers real patient stories, including individuals with significant fear of hypoglycemia and lower health and tech literacy, who saw meaningful improvements in time in range and A1C after starting on Omnipod 5. Dr. Hussain closes with a discussion on why simplicity and the tubeless form factor can be the deciding factor for patients who were previously hesitant to try pump therapy.  Whether you're a clinician, educator, or someone living with diabetes, this episode offers a compelling look at how real-world data is shaping the future of diabetes care.   00:00 - Why real-world evidence (RWE) matters 05:12 - Key real-world insights: Equity, simplicity, and outcomes  08:12 - Optimizing Omnipod 5 settings for improved clinical results 15:24 - Expanding access: Patient success stories and the power of simplicity   1. Sawyer A, et al. Diabetes Technol Ther. 2026 (T1D). Data on file. 2026. RF-062026-00044 (T2D). Retrospective RWE of U.S. T1D and U.S. T2D users utilizing optimized settings  including sufficient CGM data (≥75% of days with ≥220 readings), ≥90% time in Automated Mode, and ≥5 bolus/day (T1D) or ≥3 bolus/day (T2D). Optimized settings: CF x TDI ≤1500, I:C Ratio x TDI ≤350, Average Target Glucose of 110-115 mg/dL. How do medical devices like Omnipod 5 improve the lives of people living with diabetes? How can Healthcare Professionals implement Omnipod 5 Automated Insulin Delivery (AID) Systems in practice? Beyond the Bolus is a US-based diabetes education podcast for healthcare professionals who treat patients living with type 1 (T1D) and type 2 diabetes (T2D). Hosted by Insulet's Clinical Services Managers, Nancy Hanna RN, BSN, CDE, and Dena Gottesman MS, RD, CDCES, this dynamic duo care deeply about helping healthcare professionals (HCP)'s and patients simplify life with diabetes. Episodes cover a range of topics such as, how to get started with Omnipod 5 to ongoing care management, helping HCPs make patient conversations more efficient and effective. Beyond the Bolus also dives into the latest clinical research and data with prominent diabetes experts from across the globe who share real-world experiences and offer insights into what the future of diabetes care could look like with devices like Omnipod 5. If you're looking to empower your patients to take back control of their diabetes, then this is the podcast for you. Tue, 11 Aug 2026 10:00:00 -0000 full Insulet, Maker of Omnipod Recorded live at the ADA Scientific Sessions New Orleans, Nancy Hanna sits down with Dr. Sufyan Hussain, Consultant Physician in Diabetes and Endocrinology at Guy's and St Thomas' NHS Foundation Trust and Honorary Academic at King's College London, to explore why real-world evidence matters as much as clinical trial data.  Dr. Hussain shares how real-world data helped secure widescale public funding for automated insulin delivery (AID) systems in the UK, and walks through practical, evidence-based recommendations for healthcare providers: using stronger Target Glucose, Insulin-to-Carb ratio (≤350/TDI) and Correction Factor (≤1500/TDI) settings1. He also discusses the importance of an independent, validated comparator like lab-based A1C when evaluating outcomes across systems.  The conversation also covers real patient stories, including individuals with significant fear of hypoglycemia and lower health and tech literacy, who saw meaningful improvements in time in range and A1C after starting on Omnipod 5. Dr. Hussain closes with a discussion on why simplicity and the tubeless form factor can be the deciding factor for patients who were previously hesitant to try pump therapy.  Whether you're a clinician, educator, or someone living with diabetes, this episode offers a compelling look at how real-world data is shaping the future of diabetes care.   00:00 - Why real-world evidence (RWE) matters 05:12 - Key real-world insights: Equity, simplicity, and outcomes  08:12 - Optimizing Omnipod 5 settings for improved clinical results 15:24 - Expanding access: Patient success stories and the power of simplicity   1. Sawyer A, et al. Diabetes Technol Ther. 2026 (T1D). Data on file. 2026. RF-062026-00044 (T2D). Retrospective RWE of U.S. T1D and U.S. T2D users utilizing optimized settings  including sufficient CGM data (≥75% of days with ≥220 readings), ≥90% time in Automated Mode, and ≥5 bolus/day (T1D) or ≥3 bolus/day (T2D). Optimized settings: CF x TDI ≤1500, I:C Ratio x TDI ≤350, Average Target Glucose of 110-115 mg/dL. How do medical devices like Omnipod 5 improve the lives of people living with diabetes? How can Healthcare Professionals implement Omnipod 5 Automated Insulin Delivery (AID) Systems in practice? Beyond the Bolus is a US-based diabetes education podcast for healthcare professionals who treat patients living with type 1 (T1D) and type 2 diabetes (T2D). Hosted by Insulet's Clinical Services Managers, Nancy Hanna RN, BSN, CDE, and Dena Gottesman MS, RD, CDCES, this dynamic duo care deeply about helping healthcare professionals (HCP)'s and patients simplify life with diabetes. Episodes cover a range of topics such as, how to get started with Omnipod 5 to ongoing care management, helping HCPs make patient conversations more efficient and effective. Beyond the Bolus also dives into the latest clinical research and data with prominent diabetes experts from across the globe who share real-world experiences and offer insights into what the future of diabetes care could look like with devices like Omnipod 5. If you're looking to empower your patients to take back control of their diabetes, then this is the podcast for you. Recorded live at the ADA Scientific Sessions New Orleans, Nancy Hanna sits down with Dr. Sufyan Hussain, Consultant Physician in Diabetes and Endocrinology at Guy's and St Thomas' NHS Foundation Trust and Honorary Academic at King's College London, to explore why real-world evidence matters as much as clinical trial data.

 Dr. Hussain shares how real-world data helped secure widescale public funding for automated insulin delivery (AID) systems in the UK, and walks through practical, evidence-based recommendations for healthcare providers: using stronger Target Glucose, Insulin-to-Carb ratio (≤350/TDI) and Correction Factor (≤1500/TDI) settings1. He also discusses the importance of an independent, validated comparator like lab-based A1C when evaluating outcomes across systems.

 The conversation also covers real patient stories, including individuals with significant fear of hypoglycemia and lower health and tech literacy, who saw meaningful improvements in time in range and A1C after starting on Omnipod 5. Dr. Hussain closes with a discussion on why simplicity and the tubeless form factor can be the deciding factor for patients who were previously hesitant to try pump therapy.

 Whether you're a clinician, educator, or someone living with diabetes, this episode offers a compelling look at how real-world data is shaping the future of diabetes care.

  00:00 - Why real-world evidence (RWE) matters

05:12 - Key real-world insights: Equity, simplicity, and outcomes 

08:12 - Optimizing Omnipod 5 settings for improved clinical results

15:24 - Expanding access: Patient success stories and the power of simplicity

 

1. Sawyer A, et al. Diabetes Technol Ther. 2026 (T1D). Data on file. 2026. RF-062026-00044 (T2D). Retrospective RWE of U.S. T1D and U.S. T2D users utilizing optimized settings  including sufficient CGM data (≥75% of days with ≥220 readings), ≥90% time in Automated Mode, and ≥5 bolus/day (T1D) or ≥3 bolus/day (T2D). Optimized settings: CF x TDI ≤1500, I:C Ratio x TDI ≤350, Average Target Glucose of 110-115 mg/dL.

How do medical devices like Omnipod 5 improve the lives of people living with diabetes? How can Healthcare Professionals implement Omnipod 5 Automated Insulin Delivery (AID) Systems in practice?

Beyond the Bolus is a US-based diabetes education podcast for healthcare professionals who treat patients living with type 1 (T1D) and type 2 diabetes (T2D).

Hosted by Insulet's Clinical Services Managers, Nancy Hanna RN, BSN, CDE, and Dena Gottesman MS, RD, CDCES, this dynamic duo care deeply about helping healthcare professionals (HCP)'s and patients simplify life with diabetes. Episodes cover a range of topics such as, how to get started with Omnipod 5 to ongoing care management, helping HCPs make patient conversations more efficient and effective.

Beyond the Bolus also dives into the latest clinical research and data with prominent diabetes experts from across the globe who share real-world experiences and offer insights into what the future of diabetes care could look like with devices like Omnipod 5.

If you're looking to empower your patients to take back control of their diabetes, then this is the podcast for you.

]]> 1428 Enhanced Omnipod 5 Algorithm, Improved Outcomes, and What’s Next: Insulet’s ADA 2026 Highlights What happens when cutting-edge innovation meets real-world results? At ADA 2026, the future of diabetes management came into sharper focus—and in this episode, we’re breaking it all down for you.  Join host Nancy Hanna alongside Medical Affairs experts Kellee Miller and Jennifer Boyd as they unpack the most exciting Insulet data emerging from this year’s Scientific Sessions in New Orleans. From the latest Omnipod® 5 enhancements—including a new lower glucose target and expanded sensor compatibilities —to early real-world insights showing meaningful gains in time in range1, the conversation is packed with breakthroughs that matter.  You’ll also get an inside look at the real-world glycemic outcomes using Omnipod Discover™, a powerful new data platform designed to enhance engagement with diabetes data2; the STRIVE trial exploring the next-generation Omnipod® 6 system*;  and a vision for a fully closed-loop system for type 2 diabetes*, designed to reduce burden, simplify care, and expand access  Whether you’re a clinician, researcher, or passionate about advancing diabetes care, this is your front-row seat to the innovations shaping what’s next.  Time stamps:   1:10 Omnipod 5 is now even stronger, with a lower Target Glucose of 100 mg/dL & more time in Automated Mode  3:16 Discover™: Designed to streamline care and deliver meaningful insights  5:32 STRIVE*: Omnipod 6 pivotal trial shows strong glycemic outcomes with fewer boluses3  8:44 EVOLUTION 3*: Pre-pivotal study for Fully Closed Loop (FCL)* for type 2 diabetes4   Standard additional description for SEO purposes:   How do medical devices like Omnipod 5 improve the lives of people living with diabetes? How can Healthcare Professionals implement Omnipod 5 Automated Insulin Delivery (AID) Systems in practice?  Beyond the Bolus is a US-based diabetes education podcast for healthcare professionals who treat patients living with type 1 (t1d) and type 2 diabetes (t2d).  Hosted by Insulet’s Clincial Services Mangers, Nancy Hanna RN, BSN, CDE, and Dena Gottesman MS, RD, CDCES, this dynamic duo care deeply about helping healthcare professionals (HCP)’s and patients simplify life with diabetes. Episodes cover a range of topics such as, how to get started with Omnipod 5 to ongoing care management, helping HCPs make patient conversations more efficient and effective.  Beyond the Bolus also dives into the latest clinical research and data with prominent diabetes experts from across the globe who share real-world experiences and offer  insights into what the future of diabetes care could look like with devices like Omnipod 5.  If you’re looking to empower your patients to take back control of their diabetes, then this is the podcast for you.  *CAUTION: Insulet’s Omnipod 6 and FCL System for type 2 diabetes are investigational devices.  Limited by federal (or United States) law to investigational use.  These products have not been reviewed by the FDA or any other regulatory agency.  Insulet data on file. 2026. Presented at ADA 2026 June 5-8, New Orleans LA RF-052026-00056  2. Insulet data on file. Pablo, M et al.  Real-World Glycemic Outcomes Using the Omnipod Discover Data Management System. RF-062026-00008  3.Insulet data on file. 2026. Presented at ADA 2026 June 5-8, New Orleans LA RF-052026-00027  4. Insulet data on file. 2026. Presented at ADA 2026 June 5-8, New Orleans LA RF-062026-00015   The Omnipod 5 Automated Insulin Delivery System is indicated for use by individuals with type 1 diabetes mellitus in persons 2 years of age and older and type 2 diabetes mellitus in persons 18 years of age and older. The Omnipod 5 System is intended for single patient, home use and requires a prescription. The Omnipod 5 Automated Insulin Delivery System is compatible with the following U-100 insulins: NovoLog®, Humalog®, Kirsty®, and Admelog®. Warning: SmartAdjust™ technology should NOT be used by anyone under the age of 2 years old. SmartAdjust™ technology should also NOT be used in people who require less than 5 units of insulin per day as the safety of the technology has not been evaluated in this population Refer to the Omnipod® 5 Automated Insulin Delivery System User Guide and www.omnipod.com/safety for complete safety information including indications, contraindications, warnings, cautions, and instructions. Warning: DO NOT start to use the Omnipod® 5 System or change settings without adequate training and guidance from a healthcare provider. Initiating and adjusting settings incorrectly can result in over-delivery or under-delivery of insulin, which could lead to hypoglycemia or hyperglycemia.  © 2026 Insulet Corporation. All rights reserved.  Wed, 08 Jul 2026 10:00:00 -0000 full Insulet, Maker of Omnipod What happens when cutting-edge innovation meets real-world results? At ADA 2026, the future of diabetes management came into sharper focus—and in this episode, we’re breaking it all down for you.  Join host Nancy Hanna alongside Medical Affairs experts Kellee Miller and Jennifer Boyd as they unpack the most exciting Insulet data emerging from this year’s Scientific Sessions in New Orleans. From the latest Omnipod® 5 enhancements—including a new lower glucose target and expanded sensor compatibilities —to early real-world insights showing meaningful gains in time in range1, the conversation is packed with breakthroughs that matter.  You’ll also get an inside look at the real-world glycemic outcomes using Omnipod Discover™, a powerful new data platform designed to enhance engagement with diabetes data2; the STRIVE trial exploring the next-generation Omnipod® 6 system*;  and a vision for a fully closed-loop system for type 2 diabetes*, designed to reduce burden, simplify care, and expand access  Whether you’re a clinician, researcher, or passionate about advancing diabetes care, this is your front-row seat to the innovations shaping what’s next.  Time stamps:   1:10 Omnipod 5 is now even stronger, with a lower Target Glucose of 100 mg/dL & more time in Automated Mode  3:16 Discover™: Designed to streamline care and deliver meaningful insights  5:32 STRIVE*: Omnipod 6 pivotal trial shows strong glycemic outcomes with fewer boluses3  8:44 EVOLUTION 3*: Pre-pivotal study for Fully Closed Loop (FCL)* for type 2 diabetes4   Standard additional description for SEO purposes:   How do medical devices like Omnipod 5 improve the lives of people living with diabetes? How can Healthcare Professionals implement Omnipod 5 Automated Insulin Delivery (AID) Systems in practice?  Beyond the Bolus is a US-based diabetes education podcast for healthcare professionals who treat patients living with type 1 (t1d) and type 2 diabetes (t2d).  Hosted by Insulet’s Clincial Services Mangers, Nancy Hanna RN, BSN, CDE, and Dena Gottesman MS, RD, CDCES, this dynamic duo care deeply about helping healthcare professionals (HCP)’s and patients simplify life with diabetes. Episodes cover a range of topics such as, how to get started with Omnipod 5 to ongoing care management, helping HCPs make patient conversations more efficient and effective.  Beyond the Bolus also dives into the latest clinical research and data with prominent diabetes experts from across the globe who share real-world experiences and offer  insights into what the future of diabetes care could look like with devices like Omnipod 5.  If you’re looking to empower your patients to take back control of their diabetes, then this is the podcast for you.  *CAUTION: Insulet’s Omnipod 6 and FCL System for type 2 diabetes are investigational devices.  Limited by federal (or United States) law to investigational use.  These products have not been reviewed by the FDA or any other regulatory agency.  Insulet data on file. 2026. Presented at ADA 2026 June 5-8, New Orleans LA RF-052026-00056  2. Insulet data on file. Pablo, M et al.  Real-World Glycemic Outcomes Using the Omnipod Discover Data Management System. RF-062026-00008  3.Insulet data on file. 2026. Presented at ADA 2026 June 5-8, New Orleans LA RF-052026-00027  4. Insulet data on file. 2026. Presented at ADA 2026 June 5-8, New Orleans LA RF-062026-00015   The Omnipod 5 Automated Insulin Delivery System is indicated for use by individuals with type 1 diabetes mellitus in persons 2 years of age and older and type 2 diabetes mellitus in persons 18 years of age and older. The Omnipod 5 System is intended for single patient, home use and requires a prescription. The Omnipod 5 Automated Insulin Delivery System is compatible with the following U-100 insulins: NovoLog®, Humalog®, Kirsty®, and Admelog®. Warning: SmartAdjust™ technology should NOT be used by anyone under the age of 2 years old. SmartAdjust™ technology should also NOT be used in people who require less than 5 units of insulin per day as the safety of the technology has not been evaluated in this population Refer to the Omnipod® 5 Automated Insulin Delivery System User Guide and www.omnipod.com/safety for complete safety information including indications, contraindications, warnings, cautions, and instructions. Warning: DO NOT start to use the Omnipod® 5 System or change settings without adequate training and guidance from a healthcare provider. Initiating and adjusting settings incorrectly can result in over-delivery or under-delivery of insulin, which could lead to hypoglycemia or hyperglycemia.  © 2026 Insulet Corporation. All rights reserved.  What happens when cutting-edge innovation meets real-world results? At ADA 2026, the future of diabetes management came into sharper focus—and in this episode, we’re breaking it all down for you. 

Join host Nancy Hanna alongside Medical Affairs experts Kellee Miller and Jennifer Boyd as they unpack the most exciting Insulet data emerging from this year’s Scientific Sessions in New Orleans. From the latest Omnipod® 5 enhancements—including a new lower glucose target and expanded sensor compatibilities —to early real-world insights showing meaningful gains in time in range1, the conversation is packed with breakthroughs that matter. 

You’ll also get an inside look at the real-world glycemic outcomes using Omnipod Discover™, a powerful new data platform designed to enhance engagement with diabetes data2; the STRIVE trial exploring the next-generation Omnipod® 6 system*;  and a vision for a fully closed-loop system for type 2 diabetes*, designed to reduce burden, simplify care, and expand access 

Whether you’re a clinician, researcher, or passionate about advancing diabetes care, this is your front-row seat to the innovations shaping what’s next. 

Time stamps:  

  • 1:10 Omnipod 5 is now even stronger, with a lower Target Glucose of 100 mg/dL & more time in Automated Mode 

  • 3:16 Discover™: Designed to streamline care and deliver meaningful insights 

  • 5:32 STRIVE*: Omnipod 6 pivotal trial shows strong glycemic outcomes with fewer boluses3 

  • 8:44 EVOLUTION 3*: Pre-pivotal study for Fully Closed Loop (FCL)* for type 2 diabetes4 

 Standard additional description for SEO purposes:  

How do medical devices like Omnipod 5 improve the lives of people living with diabetes? How can Healthcare Professionals implement Omnipod 5 Automated Insulin Delivery (AID) Systems in practice? 

Beyond the Bolus is a US-based diabetes education podcast for healthcare professionals who treat patients living with type 1 (t1d) and type 2 diabetes (t2d). 

Hosted by Insulet’s Clincial Services Mangers, Nancy Hanna RN, BSN, CDE, and Dena Gottesman MS, RD, CDCES, this dynamic duo care deeply about helping healthcare professionals (HCP)’s and patients simplify life with diabetes. Episodes cover a range of topics such as, how to get started with Omnipod 5 to ongoing care management, helping HCPs make patient conversations more efficient and effective. 

Beyond the Bolus also dives into the latest clinical research and data with prominent diabetes experts from across the globe who share real-world experiences and offer 

insights into what the future of diabetes care could look like with devices like Omnipod 5. 

If you’re looking to empower your patients to take back control of their diabetes, then this is the podcast for you. 

*CAUTION: Insulet’s Omnipod 6 and FCL System for type 2 diabetes are investigational devices.  Limited by federal (or United States) law to investigational use.  These products have not been reviewed by the FDA or any other regulatory agency. 

  1. Insulet data on file. 2026. Presented at ADA 2026 June 5-8, New Orleans LA RF-052026-00056 

    2. Insulet data on file. Pablo, M et al.  Real-World Glycemic Outcomes Using the Omnipod Discover Data Management System. RF-062026-00008 

    3.Insulet data on file. 2026. Presented at ADA 2026 June 5-8, New Orleans LA RF-052026-00027 

    4. Insulet data on file. 2026. Presented at ADA 2026 June 5-8, New Orleans LA RF-062026-00015 

 The Omnipod 5 Automated Insulin Delivery System is indicated for use by individuals with type 1 diabetes mellitus in persons 2 years of age and older and type 2 diabetes mellitus in persons 18 years of age and older. The Omnipod 5 System is intended for single patient, home use and requires a prescription. The Omnipod 5 Automated Insulin Delivery System is compatible with the following U-100 insulins: NovoLog®, Humalog®, Kirsty®, and Admelog®. Warning: SmartAdjust™ technology should NOT be used by anyone under the age of 2 years old. SmartAdjust™ technology should also NOT be used in people who require less than 5 units of insulin per day as the safety of the technology has not been evaluated in this population Refer to the Omnipod® 5 Automated Insulin Delivery System User Guide and www.omnipod.com/safety for complete safety information including indications, contraindications, warnings, cautions, and instructions. Warning: DO NOT start to use the Omnipod® 5 System or change settings without adequate training and guidance from a healthcare provider. Initiating and adjusting settings incorrectly can result in over-delivery or under-delivery of insulin, which could lead to hypoglycemia or hyperglycemia. 

© 2026 Insulet Corporation. All rights reserved. 

]]> 870 Omnipod® 5's 100 mg/dL Target Glucose setting and FreeStyle Libre 3 Plus sensor integration Omnipod 5 is now even stronger with enhancements designed for more time in range1 and more time in Automated Mode. In this episode, we break down what they are and what they look like in practice. Hosts Dena Gottesman MS, RD, CDCES and Nancy Hanna RN, BSN, CDE are joined by Dr. Nader Kasim, a pediatric endocrinologist at Corewell Health living with type 1 diabetes, to explore the latest updates coming to Omnipod 5. Dr. Kasim shares his firsthand experience as a participant of the Limited Market Release of this product.  He shares how the new 100 mg/dL Target Glucose setting increases the algorithm’s response to rising glucose levels to help him spend more time in range1  and how these enhancements can help keep users in Automated Mode longer. The FreeStyle Libre 3 Plus sensor integration results in more personalized care and more real-time glucose monitoring data for caregivers with the LibreLinkUp app.  1. In a simulated analysis, the 100 mg/dL Target Glucose (TG) setting demonstrated superior Time in Range (70-180 mg/dL) compared with results at the 110-150 mg/dL TG settings in a real-world population of people with T1D using Omnipod 5. Differences in mean TIR for 100mg/dL vs 110mg/dL, vs 120 mg/dL, vs 130 mg/dL, vs 140 mg/dL, vs 150 mg/dL, were 2.5%, 4.8%, 9.8%, 15.3%, and 20.8%, respectively. For each comparison, the lower bound of the one-sided 95% Confidence Interval (CI) was >0%, meeting the pre-specified superiority criterion. Analysis not controlled for ISF, ICR, % time in Automated Mode and number of bolus/day. Data on File. RF-012026-00057. 2:33 – More TIR with the 100mg/dL Target Glucose setting1 6:04 – How adjustable Target Glucose settings support confidence in day-to-day diabetes management 10:30 – Algorithm improvements designed for more time in Automated Mode      14:41 – Sensor choice and how some Libre 3 Plus sensor choice can help families simplify care   1. In a simulated analysis, the 100 mg/dL Target Glucose (TG) setting demonstrated superior Time in Range (70-180 mg/dL) compared with results at the 110-150 mg/dL TG settings in a real-world population of people with T1D using Omnipod 5. Differences in mean TIR for 100mg/dL vs 110mg/dL, vs 120 mg/dL, vs 130 mg/dL, vs 140 mg/dL, vs 150 mg/dL, were 2.5%, 4.8%, 9.8%, 15.3%, and 20.8%, respectively. For each comparison, the lower bound of the one-sided 95% Confidence Interval (CI) was >0%, meeting the pre-specified superiority criterion. Analysis not controlled for ISF, ICR, % time in Automated Mode and number of bolus/day. Data on File. RF-012026-00057. Standard additional description for SEO purposes: [MU2] How [MU3] do medical devices like Omnipod 5 improve the lives of people living with diabetes? How can Healthcare Professionals implement Omnipod 5 Automated Insulin Delivery (AID) Systems in practice? Beyond the Bolus is a US-based diabetes education podcast for healthcare professionals who treat patients living with type 1 (t1d) and type 2 diabetes (t2d). Hosted by Insulet’s Clincial Services Mangers, Nancy Hanna RN, BSN, CDE, and Dena Gottesman MS, RD, CDCES, this dynamic duo care deeply about helping healthcare professionals (HCP)’s and patients simplify life with diabetes. Episodes cover a range of topics such as, how to get started with Omnipod 5 to ongoing care management, helping HCPs make patient conversations more efficient and effective. Beyond the Bolus also dives into the latest clinical research and data with prominent diabetes experts from across the globe who share real-world experiences and offer insights into what the future of diabetes care could look like with devices like Omnipod 5. If you’re looking to empower your patients to take back control of their diabetes, then this is the podcast for you. The Omnipod 5 Automated Insulin Delivery System is a single hormone insulin delivery system intended to deliver U-100 insulin subcutaneously for the management of type 1 diabetes in persons aged 2 and older and type 2 diabetes in persons aged 18 and older. Rx only. WARNING: Do not use SmartAdjust™ technology for people under the age of 2 or who require less than 5 U of insulin per day. Visit omnipod.com/safety for complete safety information. © 2026 Insulet Corporation. All rights reserved. Wed, 03 Jun 2026 16:00:00 -0000 full Insulet, Maker of Omnipod Omnipod 5 is now even stronger with enhancements designed for more time in range1 and more time in Automated Mode. In this episode, we break down what they are and what they look like in practice. Hosts Dena Gottesman MS, RD, CDCES and Nancy Hanna RN, BSN, CDE are joined by Dr. Nader Kasim, a pediatric endocrinologist at Corewell Health living with type 1 diabetes, to explore the latest updates coming to Omnipod 5. Dr. Kasim shares his firsthand experience as a participant of the Limited Market Release of this product.  He shares how the new 100 mg/dL Target Glucose setting increases the algorithm’s response to rising glucose levels to help him spend more time in range1  and how these enhancements can help keep users in Automated Mode longer. The FreeStyle Libre 3 Plus sensor integration results in more personalized care and more real-time glucose monitoring data for caregivers with the LibreLinkUp app.  1. In a simulated analysis, the 100 mg/dL Target Glucose (TG) setting demonstrated superior Time in Range (70-180 mg/dL) compared with results at the 110-150 mg/dL TG settings in a real-world population of people with T1D using Omnipod 5. Differences in mean TIR for 100mg/dL vs 110mg/dL, vs 120 mg/dL, vs 130 mg/dL, vs 140 mg/dL, vs 150 mg/dL, were 2.5%, 4.8%, 9.8%, 15.3%, and 20.8%, respectively. For each comparison, the lower bound of the one-sided 95% Confidence Interval (CI) was >0%, meeting the pre-specified superiority criterion. Analysis not controlled for ISF, ICR, % time in Automated Mode and number of bolus/day. Data on File. RF-012026-00057. 2:33 – More TIR with the 100mg/dL Target Glucose setting1 6:04 – How adjustable Target Glucose settings support confidence in day-to-day diabetes management 10:30 – Algorithm improvements designed for more time in Automated Mode      14:41 – Sensor choice and how some Libre 3 Plus sensor choice can help families simplify care   1. In a simulated analysis, the 100 mg/dL Target Glucose (TG) setting demonstrated superior Time in Range (70-180 mg/dL) compared with results at the 110-150 mg/dL TG settings in a real-world population of people with T1D using Omnipod 5. Differences in mean TIR for 100mg/dL vs 110mg/dL, vs 120 mg/dL, vs 130 mg/dL, vs 140 mg/dL, vs 150 mg/dL, were 2.5%, 4.8%, 9.8%, 15.3%, and 20.8%, respectively. For each comparison, the lower bound of the one-sided 95% Confidence Interval (CI) was >0%, meeting the pre-specified superiority criterion. Analysis not controlled for ISF, ICR, % time in Automated Mode and number of bolus/day. Data on File. RF-012026-00057. Standard additional description for SEO purposes: [MU2] How [MU3] do medical devices like Omnipod 5 improve the lives of people living with diabetes? How can Healthcare Professionals implement Omnipod 5 Automated Insulin Delivery (AID) Systems in practice? Beyond the Bolus is a US-based diabetes education podcast for healthcare professionals who treat patients living with type 1 (t1d) and type 2 diabetes (t2d). Hosted by Insulet’s Clincial Services Mangers, Nancy Hanna RN, BSN, CDE, and Dena Gottesman MS, RD, CDCES, this dynamic duo care deeply about helping healthcare professionals (HCP)’s and patients simplify life with diabetes. Episodes cover a range of topics such as, how to get started with Omnipod 5 to ongoing care management, helping HCPs make patient conversations more efficient and effective. Beyond the Bolus also dives into the latest clinical research and data with prominent diabetes experts from across the globe who share real-world experiences and offer insights into what the future of diabetes care could look like with devices like Omnipod 5. If you’re looking to empower your patients to take back control of their diabetes, then this is the podcast for you. The Omnipod 5 Automated Insulin Delivery System is a single hormone insulin delivery system intended to deliver U-100 insulin subcutaneously for the management of type 1 diabetes in persons aged 2 and older and type 2 diabetes in persons aged 18 and older. Rx only. WARNING: Do not use SmartAdjust™ technology for people under the age of 2 or who require less than 5 U of insulin per day. Visit omnipod.com/safety for complete safety information. © 2026 Insulet Corporation. All rights reserved. Omnipod 5 is now even stronger with enhancements designed for more time in range1 and more time in Automated Mode. In this episode, we break down what they are and what they look like in practice.

Hosts Dena Gottesman MS, RD, CDCES and Nancy Hanna RN, BSN, CDE are joined by Dr. Nader Kasim, a pediatric endocrinologist at Corewell Health living with type 1 diabetes, to explore the latest updates coming to Omnipod 5.

Dr. Kasim shares his firsthand experience as a participant of the Limited Market Release of this product.  He shares how the new 100 mg/dL Target Glucose setting increases the algorithm’s response to rising glucose levels to help him spend more time in range1  and how these enhancements can help keep users in Automated Mode longer.

The FreeStyle Libre 3 Plus sensor integration results in more personalized care and more real-time glucose monitoring data for caregivers with the LibreLinkUp app.

 1. In a simulated analysis, the 100 mg/dL Target Glucose (TG) setting demonstrated superior Time in Range (70-180 mg/dL) compared with results at the 110-150 mg/dL TG settings in a real-world population of people with T1D using Omnipod 5. Differences in mean TIR for 100mg/dL vs 110mg/dL, vs 120 mg/dL, vs 130 mg/dL, vs 140 mg/dL, vs 150 mg/dL, were 2.5%, 4.8%, 9.8%, 15.3%, and 20.8%, respectively. For each comparison, the lower bound of the one-sided 95% Confidence Interval (CI) was >0%, meeting the pre-specified superiority criterion. Analysis not controlled for ISF, ICR, % time in Automated Mode and number of bolus/day. Data on File. RF-012026-00057.

2:33 – More TIR with the 100mg/dL Target Glucose setting1 6:04 – How adjustable Target Glucose settings support confidence in day-to-day diabetes management 10:30 – Algorithm improvements designed for more time in Automated Mode      14:41 – Sensor choice and how some Libre 3 Plus sensor choice can help families simplify care

 

1. In a simulated analysis, the 100 mg/dL Target Glucose (TG) setting demonstrated superior Time in Range (70-180 mg/dL) compared with results at the 110-150 mg/dL TG settings in a real-world population of people with T1D using Omnipod 5. Differences in mean TIR for 100mg/dL vs 110mg/dL, vs 120 mg/dL, vs 130 mg/dL, vs 140 mg/dL, vs 150 mg/dL, were 2.5%, 4.8%, 9.8%, 15.3%, and 20.8%, respectively. For each comparison, the lower bound of the one-sided 95% Confidence Interval (CI) was >0%, meeting the pre-specified superiority criterion. Analysis not controlled for ISF, ICR, % time in Automated Mode and number of bolus/day. Data on File. RF-012026-00057.

Standard additional description for SEO purposes: [MU2] How [MU3] do medical devices like Omnipod 5 improve the lives of people living with diabetes? How can Healthcare Professionals implement Omnipod 5 Automated Insulin Delivery (AID) Systems in practice?

Beyond the Bolus is a US-based diabetes education podcast for healthcare professionals who treat patients living with type 1 (t1d) and type 2 diabetes (t2d).

Hosted by Insulet’s Clincial Services Mangers, Nancy Hanna RN, BSN, CDE, and Dena Gottesman MS, RD, CDCES, this dynamic duo care deeply about helping healthcare professionals (HCP)’s and patients simplify life with diabetes. Episodes cover a range of topics such as, how to get started with Omnipod 5 to ongoing care management, helping HCPs make patient conversations more efficient and effective.

Beyond the Bolus also dives into the latest clinical research and data with prominent diabetes experts from across the globe who share real-world experiences and offer insights into what the future of diabetes care could look like with devices like Omnipod 5.

If you’re looking to empower your patients to take back control of their diabetes, then this is the podcast for you.


The Omnipod 5 Automated Insulin Delivery System is a single hormone insulin delivery system intended to deliver U-100 insulin subcutaneously for the management of type 1 diabetes in persons aged 2 and older and type 2 diabetes in persons aged 18 and older. Rx only. WARNING: Do not use SmartAdjust™ technology for people under the age of 2 or who require less than 5 U of insulin per day. Visit omnipod.com/safety for complete safety information.

© 2026 Insulet Corporation. All rights reserved.




]]> 1327 Mental Health, Automation, and Human-Centered Design: Rethinking Diabetes Care with AID Systems Mental health, cognitive burden, and quality of life are becoming central to how we define success in diabetes care. In this episode, we explore what that shift looks like in practice. Hosts Dena Gottesman MS, RD, CDCES and Nancy Hanna RN, BSN, CDE hand over to guest host Kamil Armacki , also known as Nerdabetic, who is joined by Dr. Korey Hood, Clinical Psychologist and Professor at Stanford University, and Jen Boyd, Senior Director of Medical Affairs at Insulet. Together, they unpack the often overlooked mental and cognitive load of living with diabetes, from constant decision making and planning to sleep disruption and diabetes distress. Dr Hood shares both his clinical expertise and personal perspective as someone living with type 1 (t1d) diabetes, highlighting why these challenges are just as important as glycemic outcomes. The conversation explores how advancements in automated insulin delivery (AID) and human-centered design are helping reduce that burden. Jen Boyd discusses how simplicity, usability, and patient feedback shape the development of technologies like Omnipod 5, with a focus on removing friction from everyday diabetes management. It is a powerful reminder that diabetes care is not just about time in range, but about creating more time for living.• 03:03– Mental & cognitive burden of diabetes• 07:26 – Usability and outcomes are inseparable• 10:18 – Automated insulin delivery reduces burden and restores freedom• 18:20 – Shift from numbers to lived experience How do medical devices like Omnipod 5 improve the lives of people living with diabetes? How can Healthcare Professionals implement Omnipod 5 Automated Insulin Delivery (AID) Systems in practice? Beyond the Bolus is a US-based diabetes education podcast for healthcare professionals who treat patients living with type 1 (t1d) and type 2 diabetes (t2d). Hosted by Insulet’s Clincial Services Mangers, Nancy Hanna RN, BSN, CDE, and Dena Gottesman MS, RD, CDCES, this dynamic duo care deeply about helping healthcare professionals (HCP)’s and patients simplify life with diabetes. Episodes cover a range of topics such as, how to get started with Omnipod 5 to ongoing care management, helping HCPs make patient conversations more efficient and effective. Beyond the Bolus also dives into the latest clinical research and data with prominent diabetes experts from across the globe who share real-world experiences and offer insights into what the future of diabetes care could look like with devices like Omnipod 5. If you’re looking to empower your patients to take back control of their diabetes, then this is the podcast for you. The Omnipod 5 Automated Insulin Delivery System is a single hormone insulin delivery system intended to deliver U-100 insulin subcutaneously for the management of type 1 diabetes in persons aged 2 and older and type 2 diabetes in persons aged 18 and older. Rx only. WARNING: Do not use SmartAdjust™ technology for people under the age of 2 or who require less than 5 U of insulin per day. Visit omnipod.com/safety for complete safety information. © 2026 Insulet Corporation. All rights reserved Mon, 18 May 2026 16:00:00 -0000 full Insulet, Maker of Omnipod Mental health, cognitive burden, and quality of life are becoming central to how we define success in diabetes care. In this episode, we explore what that shift looks like in practice. Hosts Dena Gottesman MS, RD, CDCES and Nancy Hanna RN, BSN, CDE hand over to guest host Kamil Armacki , also known as Nerdabetic, who is joined by Dr. Korey Hood, Clinical Psychologist and Professor at Stanford University, and Jen Boyd, Senior Director of Medical Affairs at Insulet. Together, they unpack the often overlooked mental and cognitive load of living with diabetes, from constant decision making and planning to sleep disruption and diabetes distress. Dr Hood shares both his clinical expertise and personal perspective as someone living with type 1 (t1d) diabetes, highlighting why these challenges are just as important as glycemic outcomes. The conversation explores how advancements in automated insulin delivery (AID) and human-centered design are helping reduce that burden. Jen Boyd discusses how simplicity, usability, and patient feedback shape the development of technologies like Omnipod 5, with a focus on removing friction from everyday diabetes management. It is a powerful reminder that diabetes care is not just about time in range, but about creating more time for living.• 03:03– Mental & cognitive burden of diabetes• 07:26 – Usability and outcomes are inseparable• 10:18 – Automated insulin delivery reduces burden and restores freedom• 18:20 – Shift from numbers to lived experience How do medical devices like Omnipod 5 improve the lives of people living with diabetes? How can Healthcare Professionals implement Omnipod 5 Automated Insulin Delivery (AID) Systems in practice? Beyond the Bolus is a US-based diabetes education podcast for healthcare professionals who treat patients living with type 1 (t1d) and type 2 diabetes (t2d). Hosted by Insulet’s Clincial Services Mangers, Nancy Hanna RN, BSN, CDE, and Dena Gottesman MS, RD, CDCES, this dynamic duo care deeply about helping healthcare professionals (HCP)’s and patients simplify life with diabetes. Episodes cover a range of topics such as, how to get started with Omnipod 5 to ongoing care management, helping HCPs make patient conversations more efficient and effective. Beyond the Bolus also dives into the latest clinical research and data with prominent diabetes experts from across the globe who share real-world experiences and offer insights into what the future of diabetes care could look like with devices like Omnipod 5. If you’re looking to empower your patients to take back control of their diabetes, then this is the podcast for you. The Omnipod 5 Automated Insulin Delivery System is a single hormone insulin delivery system intended to deliver U-100 insulin subcutaneously for the management of type 1 diabetes in persons aged 2 and older and type 2 diabetes in persons aged 18 and older. Rx only. WARNING: Do not use SmartAdjust™ technology for people under the age of 2 or who require less than 5 U of insulin per day. Visit omnipod.com/safety for complete safety information. © 2026 Insulet Corporation. All rights reserved Mental health, cognitive burden, and quality of life are becoming central to how we define success in diabetes care. In this episode, we explore what that shift looks like in practice.

Hosts Dena Gottesman MS, RD, CDCES and Nancy Hanna RN, BSN, CDE hand over to guest host Kamil Armacki , also known as Nerdabetic, who is joined by Dr. Korey Hood, Clinical Psychologist and Professor at Stanford University, and Jen Boyd, Senior Director of Medical Affairs at Insulet.

Together, they unpack the often overlooked mental and cognitive load of living with diabetes, from constant decision making and planning to sleep disruption and diabetes distress. Dr Hood shares both his clinical expertise and personal perspective as someone living with type 1 (t1d) diabetes, highlighting why these challenges are just as important as glycemic outcomes.

The conversation explores how advancements in automated insulin delivery (AID) and human-centered design are helping reduce that burden. Jen Boyd discusses how simplicity, usability, and patient feedback shape the development of technologies like Omnipod 5, with a focus on removing friction from everyday diabetes management. It is a powerful reminder that diabetes care is not just about time in range, but about creating more time for living.
• 03:03– Mental & cognitive burden of diabetes
• 07:26 – Usability and outcomes are inseparable
• 10:18 – Automated insulin delivery reduces burden and restores freedom
• 18:20 – Shift from numbers to lived experience


How do medical devices like Omnipod 5 improve the lives of people living with diabetes?

How can Healthcare Professionals implement Omnipod 5 Automated Insulin Delivery (AID) Systems in practice?

Beyond the Bolus is a US-based diabetes education podcast for healthcare professionals who treat patients living with type 1 (t1d) and type 2 diabetes (t2d).

Hosted by Insulet’s Clincial Services Mangers, Nancy Hanna RN, BSN, CDE, and Dena Gottesman MS, RD, CDCES, this dynamic duo care deeply about helping healthcare professionals (HCP)’s and patients simplify life with diabetes. Episodes cover a range of topics such as, how to get started with Omnipod 5 to ongoing care management, helping HCPs make patient conversations more efficient and effective.

Beyond the Bolus also dives into the latest clinical research and data with prominent diabetes experts from across the globe who share real-world experiences and offer insights into what the future of diabetes care could look like with devices like Omnipod 5. If you’re looking to empower your patients to take back control of their diabetes, then this is the podcast for you.

The Omnipod 5 Automated Insulin Delivery System is a single hormone insulin delivery system intended to deliver U-100 insulin subcutaneously for the management of type 1 diabetes in persons aged 2 and older and type 2 diabetes in persons aged 18 and older. Rx only. WARNING: Do not use SmartAdjust™ technology for people under the age of 2 or who require less than 5 U of insulin per day. Visit omnipod.com/safety for complete safety information.


© 2026 Insulet Corporation. All rights reserved

]]> 1297 The Benefits of Insulet’s Pod Recycling Program How do you make diabetes care more sustainable? We’re addressing patient concerns regarding medical waste, enhancing the sustainability profile of the practice's treatment recommendations, and fostering higher patient satisfaction with the Insulet’s Pod Recycling Program. Hosts Dena Gottesman MS, RD, CDCES and Nancy Hanna RN, BSN, CDE are joined by Lisa Brady, Vice President and Chief Sustainability Officer at Insulet, to explore how the company is tackling one of the biggest challenges in diabetes technology – waste. Lisa walks through Insulet’s Pod recycling program, which has now expanded across the United States. Omnipod® 5 users can request a simple, accessible return kit, which can hold up to 6 months' worth of Pods. Once returned, Lisa explains the decontamination process and how batteries, plastics and metals are repurposed. This global diabetes tech recycling program is the first of many sustainability initiatives enabling Insulet to take a more active role in reducing environmental impact without increasing the burden of daily diabetes care. • 01:22 – The core pillars of Insulet’s sustainability strategy• 03:49 – A step-by-step breakdown of the recycling program• 05:06 –Why Pod recycling matters to customers and the community• 09:51 – What’s next: expansion, future access, and sustainability goals--How do medical devices like Omnipod 5 improve the lives of people living with diabetes? How can Healthcare Professionals implement Omnipod 5 Automated Insulin Delivery (AID) Systems in practice? Beyond the Bolus is a US-based diabetes education podcast for healthcare professionals who care for people living with type 1 (t1d) and type 2 diabetes (t2d). Hosted by Insulet’s Clincial Services Mangers, Nancy Hanna RN, BSN, CDE, and Dena Gottesman MS, RD, CDCES, this dynamic duo care deeply about helping healthcare professionals (HCP)’s and patients simplify life with diabetes. Episodes cover a range of topics such as, how to get started with Omnipod 5 to ongoing care management, helping HCPs make patient conversations more efficient and effective. Beyond the Bolus also dives into the latest clinical research and data with prominent diabetes experts from across the globe who share real-world experiences and offer insights into what the future of diabetes care could look like with technology like Omnipod 5. The Omnipod 5 Automated Insulin Delivery System is a single hormone insulin delivery system intended to deliver U-100 insulin subcutaneously for the management of type 1 diabetes in persons aged 2 and older and type 2 diabetes in persons aged 18 and older. Rx only. WARNING: Do not use SmartAdjust™ technology for people under the age of 2 or who require less than 5 U of insulin per day. Visit omnipod.com/safety for complete safety information. © 2026 Insulet Corporation. All rights reserved. Wed, 22 Apr 2026 10:00:00 -0000 full Insulet, Maker of Omnipod How do you make diabetes care more sustainable? We’re addressing patient concerns regarding medical waste, enhancing the sustainability profile of the practice's treatment recommendations, and fostering higher patient satisfaction with the Insulet’s Pod Recycling Program. Hosts Dena Gottesman MS, RD, CDCES and Nancy Hanna RN, BSN, CDE are joined by Lisa Brady, Vice President and Chief Sustainability Officer at Insulet, to explore how the company is tackling one of the biggest challenges in diabetes technology – waste. Lisa walks through Insulet’s Pod recycling program, which has now expanded across the United States. Omnipod® 5 users can request a simple, accessible return kit, which can hold up to 6 months' worth of Pods. Once returned, Lisa explains the decontamination process and how batteries, plastics and metals are repurposed. This global diabetes tech recycling program is the first of many sustainability initiatives enabling Insulet to take a more active role in reducing environmental impact without increasing the burden of daily diabetes care. • 01:22 – The core pillars of Insulet’s sustainability strategy• 03:49 – A step-by-step breakdown of the recycling program• 05:06 –Why Pod recycling matters to customers and the community• 09:51 – What’s next: expansion, future access, and sustainability goals--How do medical devices like Omnipod 5 improve the lives of people living with diabetes? How can Healthcare Professionals implement Omnipod 5 Automated Insulin Delivery (AID) Systems in practice? Beyond the Bolus is a US-based diabetes education podcast for healthcare professionals who care for people living with type 1 (t1d) and type 2 diabetes (t2d). Hosted by Insulet’s Clincial Services Mangers, Nancy Hanna RN, BSN, CDE, and Dena Gottesman MS, RD, CDCES, this dynamic duo care deeply about helping healthcare professionals (HCP)’s and patients simplify life with diabetes. Episodes cover a range of topics such as, how to get started with Omnipod 5 to ongoing care management, helping HCPs make patient conversations more efficient and effective. Beyond the Bolus also dives into the latest clinical research and data with prominent diabetes experts from across the globe who share real-world experiences and offer insights into what the future of diabetes care could look like with technology like Omnipod 5. The Omnipod 5 Automated Insulin Delivery System is a single hormone insulin delivery system intended to deliver U-100 insulin subcutaneously for the management of type 1 diabetes in persons aged 2 and older and type 2 diabetes in persons aged 18 and older. Rx only. WARNING: Do not use SmartAdjust™ technology for people under the age of 2 or who require less than 5 U of insulin per day. Visit omnipod.com/safety for complete safety information. © 2026 Insulet Corporation. All rights reserved. How do you make diabetes care more sustainable? We’re addressing patient concerns regarding medical waste, enhancing the sustainability profile of the practice's treatment recommendations, and fostering higher patient satisfaction with the Insulet’s Pod Recycling Program.


Hosts Dena Gottesman MS, RD, CDCES and Nancy Hanna RN, BSN, CDE are joined by Lisa Brady, Vice President and Chief Sustainability Officer at Insulet, to explore how the company is tackling one of the biggest challenges in diabetes technology – waste.

Lisa walks through Insulet’s Pod recycling program, which has now expanded across the United States. Omnipod® 5 users can request a simple, accessible return kit, which can hold up to 6 months' worth of Pods. Once returned, Lisa explains the decontamination process and how batteries, plastics and metals are repurposed. This global diabetes tech recycling program is the first of many sustainability initiatives enabling Insulet to take a more active role in reducing environmental impact without increasing the burden of daily diabetes care.


• 01:22 – The core pillars of Insulet’s sustainability strategy
• 03:49 – A step-by-step breakdown of the recycling program
• 05:06 –Why Pod recycling matters to customers and the community
• 09:51 – What’s next: expansion, future access, and sustainability goals
--
How do medical devices like Omnipod 5 improve the lives of people living with diabetes? How can Healthcare Professionals implement Omnipod 5 Automated Insulin Delivery (AID) Systems in practice?

Beyond the Bolus is a US-based diabetes education podcast for healthcare professionals who care for people living with type 1 (t1d) and type 2 diabetes (t2d).

Hosted by Insulet’s Clincial Services Mangers, Nancy Hanna RN, BSN, CDE, and Dena Gottesman MS, RD, CDCES, this dynamic duo care deeply about helping healthcare professionals (HCP)’s and patients simplify life with diabetes. Episodes cover a range of topics such as, how to get started with Omnipod 5 to ongoing care management, helping HCPs make patient conversations more efficient and effective.

Beyond the Bolus also dives into the latest clinical research and data with prominent diabetes experts from across the globe who share real-world experiences and offer insights into what the future of diabetes care could look like with technology like Omnipod 5.


The Omnipod 5 Automated Insulin Delivery System is a single hormone insulin delivery system intended to deliver U-100 insulin subcutaneously for the management of type 1 diabetes in persons aged 2 and older and type 2 diabetes in persons aged 18 and older. Rx only. WARNING: Do not use SmartAdjust™ technology for people under the age of 2 or who require less than 5 U of insulin per day. Visit omnipod.com/safety for complete safety information.


© 2026 Insulet Corporation. All rights reserved.

]]> 916 A Clinician Love Letter to Omnipod® 5 Hosted by Nancy Hanna and Dena Gottesman In this special Valentine’s-month episode of Beyond the Bolus, hosts Nancy Hanna and Dena Gottesman share a clinician “love letter” to the Omnipod 5 Automated Insulin Delivery System — highlighting the real-world moments, patient stories, and everyday features that healthcare providers value most. Through firsthand perspectives from clinicians who both prescribe and personally use Omnipod 5, this episode explores how automated insulin delivery is changing diabetes care. Guests share why personalization matters, how tubeless design can improve adoption, and how small features (from Custom Foods to real-time data access) can make a meaningful difference in daily diabetes management.   Wed, 25 Feb 2026 06:32:00 -0000 full Insulet, Maker of Omnipod Hosted by Nancy Hanna and Dena Gottesman In this special Valentine’s-month episode of Beyond the Bolus, hosts Nancy Hanna and Dena Gottesman share a clinician “love letter” to the Omnipod 5 Automated Insulin Delivery System — highlighting the real-world moments, patient stories, and everyday features that healthcare providers value most. Through firsthand perspectives from clinicians who both prescribe and personally use Omnipod 5, this episode explores how automated insulin delivery is changing diabetes care. Guests share why personalization matters, how tubeless design can improve adoption, and how small features (from Custom Foods to real-time data access) can make a meaningful difference in daily diabetes management.   Hosted by Nancy Hanna and Dena Gottesman


In this special Valentine’s-month episode of Beyond the Bolus, hosts Nancy Hanna and Dena Gottesman share a clinician “love letter” to the Omnipod 5 Automated Insulin Delivery System — highlighting the real-world moments, patient stories, and everyday features that healthcare providers value most.


Through firsthand perspectives from clinicians who both prescribe and personally use Omnipod 5, this episode explores how automated insulin delivery is changing diabetes care.


Guests share why personalization matters, how tubeless design can improve adoption, and how small features (from Custom Foods to real-time data access) can make a meaningful difference in daily diabetes management.

 

]]> 749 Exercising with AID Systems: Practical Tips for Planned and Unplanned Activity with Dr. Desi Zaharieva In this special ADA 2025 edition of Beyond the Bolus, host Nancy Hanna sits down with Dr Dessi Zaharieva to talk about the most challenging aspects of diabetes management - Exercise. In this episode, Dr Zaharieva breaks down key takeaways from her co-authored international consensus statement on using automated insulin delivery (AID) systems during physical activity. Topics covered included how to manage planned VS unplanned exercise using AID systems, why setting a higher glucose target 1-2 hours before physical activity makes a difference and the importance of a strategic approach to carbs to help prevent hypoglycaemia. Whether you’re supporting patients in the clinic or helping them prepare for spontaneous workouts, this conversation offers evidence-based, real-world strategies to make exercise safer, simpler, and more enjoyable for people living with diabetes. Tue, 06 Jan 2026 10:33:00 -0000 full Insulet, Maker of Omnipod In this special ADA 2025 edition of Beyond the Bolus, host Nancy Hanna sits down with Dr Dessi Zaharieva to talk about the most challenging aspects of diabetes management - Exercise. In this episode, Dr Zaharieva breaks down key takeaways from her co-authored international consensus statement on using automated insulin delivery (AID) systems during physical activity. Topics covered included how to manage planned VS unplanned exercise using AID systems, why setting a higher glucose target 1-2 hours before physical activity makes a difference and the importance of a strategic approach to carbs to help prevent hypoglycaemia. Whether you’re supporting patients in the clinic or helping them prepare for spontaneous workouts, this conversation offers evidence-based, real-world strategies to make exercise safer, simpler, and more enjoyable for people living with diabetes. In this special ADA 2025 edition of Beyond the Bolus, host Nancy Hanna sits down with Dr Dessi Zaharieva to talk about the most challenging aspects of diabetes management - Exercise.


In this episode, Dr Zaharieva breaks down key takeaways from her co-authored international consensus statement on using automated insulin delivery (AID) systems during physical activity.


Topics covered included how to manage planned VS unplanned exercise using AID systems, why setting a higher glucose target 1-2 hours before physical activity makes a difference and the importance of a strategic approach to carbs to help prevent hypoglycaemia. Whether you’re supporting patients in the clinic or helping them prepare for spontaneous workouts, this conversation offers evidence-based, real-world strategies to make exercise safer, simpler, and more enjoyable for people living with diabetes.

]]> 761 Expanding Access to AID with Omnipod® 5 (featuring. Dr. Grazia Aleppo) This episode features Dr. Aleppo, an endocrinologist, who has a commercial relationship with Insulet and was compensated for her participation in the podcast.    Dr. Grazia Aleppo returns to Beyond the Bolus to share her insights from ADA 2025 and beyond. In this engaging conversation, Dr. Aleppo discusses the evolution of automated insulin delivery (AID) systems, the RADIANT and SECURE-T2D clinical trials, and why Omnipod® 5 is changing the game for people with both type 1 and type 2 diabetes. From helping patients to overcome fears of hypoglycemia to simplifying care, Dr. Aleppo emphasizes the importance of challenging outdated assumptions about who benefits from AID and underscores the need for simple, more adaptable solutions for every patient.   Tue, 02 Dec 2025 17:00:00 -0000 full Insulet, Maker of Omnipod This episode features Dr. Aleppo, an endocrinologist, who has a commercial relationship with Insulet and was compensated for her participation in the podcast.    Dr. Grazia Aleppo returns to Beyond the Bolus to share her insights from ADA 2025 and beyond. In this engaging conversation, Dr. Aleppo discusses the evolution of automated insulin delivery (AID) systems, the RADIANT and SECURE-T2D clinical trials, and why Omnipod® 5 is changing the game for people with both type 1 and type 2 diabetes. From helping patients to overcome fears of hypoglycemia to simplifying care, Dr. Aleppo emphasizes the importance of challenging outdated assumptions about who benefits from AID and underscores the need for simple, more adaptable solutions for every patient.   This episode features Dr. Aleppo, an endocrinologist, who has a commercial relationship with Insulet and was compensated for her participation in the podcast. 

 

Dr. Grazia Aleppo returns to Beyond the Bolus to share her insights from ADA 2025 and beyond. In this engaging conversation, Dr. Aleppo discusses the evolution of automated insulin delivery (AID) systems, the RADIANT and SECURE-T2D clinical trials, and why Omnipod® 5 is changing the game for people with both type 1 and type 2 diabetes. From helping patients to overcome fears of hypoglycemia to simplifying care, Dr. Aleppo emphasizes the importance of challenging outdated assumptions about who benefits from AID and underscores the need for simple, more adaptable solutions for every patient.  

]]> 1888 Tech, teens, and type 1 diabetes (featuring Dr. Dan DeSalvo) This episode features Dr. DeSalvo, a pediatric endocrinologist, who has a commercial relationship with Insulet and was compensated for his participation in the podcast. In this episode of Beyond the Bolus, Dr. Daniel DeSalvo shares his experience caring for teens with type 1 diabetes - and why this population deserves more credit than they often get. From navigating diabetes distress to celebrating wins in the classroom, on the field, and in the orchestra pit, Dr. DeSalvo highlights how Omnipod® 5 can help shift diabetes from the foreground to the background. With practical tips for system optimization and heartfelt stories of transformation, this episode is a must-listen for anyone caring for teens with type 1 diabetes. Wed, 19 Nov 2025 12:00:00 -0000 full Insulet, Maker of Omnipod This episode features Dr. DeSalvo, a pediatric endocrinologist, who has a commercial relationship with Insulet and was compensated for his participation in the podcast. In this episode of Beyond the Bolus, Dr. Daniel DeSalvo shares his experience caring for teens with type 1 diabetes - and why this population deserves more credit than they often get. From navigating diabetes distress to celebrating wins in the classroom, on the field, and in the orchestra pit, Dr. DeSalvo highlights how Omnipod® 5 can help shift diabetes from the foreground to the background. With practical tips for system optimization and heartfelt stories of transformation, this episode is a must-listen for anyone caring for teens with type 1 diabetes. This episode features Dr. DeSalvo, a pediatric endocrinologist, who has a commercial relationship with Insulet and was compensated for his participation in the podcast.


In this episode of Beyond the Bolus, Dr. Daniel DeSalvo shares his experience caring for teens with type 1 diabetes - and why this population deserves more credit than they often get. From navigating diabetes distress to celebrating wins in the classroom, on the field, and in the orchestra pit, Dr. DeSalvo highlights how Omnipod® 5 can help shift diabetes from the foreground to the background.


With practical tips for system optimization and heartfelt stories of transformation, this episode is a must-listen for anyone caring for teens with type 1 diabetes.

]]> 1738 From start to success: Real-world tips for optimization with Omnipod® 5 In this special ADA 2025 edition of Beyond the Bolus, hosts Nancy Hanna and Cindy Pickering sit down with Cari Berget, RN, CDCES from the Barbara Davis Center, to unpack the newly published paper, Practical considerations for using the Omnipod 5 Automated Insulin Delivery System: Clinical experience from the United States and Europe. Drawing on years of real-world experience, Cari shares evidence-backed strategies to start patients on AID confidently, optimize settings, personalize targets, and simplify bolusing - even without perfect carb counting. From pediatrics to older adult care, this episode is packed with actionable tips, memorable vignettes, and key takeaways to support success with Omnipod 5 across diverse patient populations. Thu, 02 Oct 2025 03:58:00 -0000 full Insulet, Maker of Omnipod In this special ADA 2025 edition of Beyond the Bolus, hosts Nancy Hanna and Cindy Pickering sit down with Cari Berget, RN, CDCES from the Barbara Davis Center, to unpack the newly published paper, Practical considerations for using the Omnipod 5 Automated Insulin Delivery System: Clinical experience from the United States and Europe. Drawing on years of real-world experience, Cari shares evidence-backed strategies to start patients on AID confidently, optimize settings, personalize targets, and simplify bolusing - even without perfect carb counting. From pediatrics to older adult care, this episode is packed with actionable tips, memorable vignettes, and key takeaways to support success with Omnipod 5 across diverse patient populations. In this special ADA 2025 edition of Beyond the Bolus, hosts Nancy Hanna and Cindy Pickering sit down with Cari Berget, RN, CDCES from the Barbara Davis Center, to unpack the newly published paper, Practical considerations for using the Omnipod 5 Automated Insulin Delivery System: Clinical experience from the United States and Europe. Drawing on years of real-world experience, Cari shares evidence-backed strategies to start patients on AID confidently, optimize settings, personalize targets, and simplify bolusing - even without perfect carb counting.

From pediatrics to older adult care, this episode is packed with actionable tips, memorable vignettes, and key takeaways to support success with Omnipod 5 across diverse patient populations.


]]> 2817 The best is yet to come: Easing the burden of diabetes for peds with Omnipod 5 (featuring Dr. Kathy Sumpter) In this heartfelt and insightful episode of Beyond the Bolus, hosts Nancy Hanna and Dena Gottesman sit down with Dr. Kathy Sumpter, a pediatric endocrinologist who brings a unique dual perspective as both a healthcare provider and someone living with type 1 diabetes. Diagnosed at age 20, Dr. Sumpter shares her personal journey and how it shaped her mission to support children and teens navigating diabetes. Together, they explore the evolution of diabetes technology, the transformative impact of the Omnipod 5 system, and how it helps families manage diabetes more confidently, from toddlers to teens. Dr. Sumpter offers practical advice for clinicians, discusses the emotional realities of diabetes care, and emphasizes the importance of meeting families where they are. Whether you're a healthcare provider, caregiver, or someone living with diabetes, this episode is packed with empathy, expertise, and inspiration. Tue, 29 Jul 2025 04:27:00 -0000 full Insulet, Maker of Omnipod In this heartfelt and insightful episode of Beyond the Bolus, hosts Nancy Hanna and Dena Gottesman sit down with Dr. Kathy Sumpter, a pediatric endocrinologist who brings a unique dual perspective as both a healthcare provider and someone living with type 1 diabetes. Diagnosed at age 20, Dr. Sumpter shares her personal journey and how it shaped her mission to support children and teens navigating diabetes. Together, they explore the evolution of diabetes technology, the transformative impact of the Omnipod 5 system, and how it helps families manage diabetes more confidently, from toddlers to teens. Dr. Sumpter offers practical advice for clinicians, discusses the emotional realities of diabetes care, and emphasizes the importance of meeting families where they are. Whether you're a healthcare provider, caregiver, or someone living with diabetes, this episode is packed with empathy, expertise, and inspiration. In this heartfelt and insightful episode of Beyond the Bolus, hosts Nancy Hanna and Dena Gottesman sit down with Dr. Kathy Sumpter, a pediatric endocrinologist who brings a unique dual perspective as both a healthcare provider and someone living with type 1 diabetes. Diagnosed at age 20, Dr. Sumpter shares her personal journey and how it shaped her mission to support children and teens navigating diabetes.


Together, they explore the evolution of diabetes technology, the transformative impact of the Omnipod 5 system, and how it helps families manage diabetes more confidently, from toddlers to teens. Dr. Sumpter offers practical advice for clinicians, discusses the emotional realities of diabetes care, and emphasizes the importance of meeting families where they are.


Whether you're a healthcare provider, caregiver, or someone living with diabetes, this episode is packed with empathy, expertise, and inspiration.

]]> 1771 Real-world impact of Omnipod® 5 in type 2 diabetes (featuring. Kellee Miller & Jennifer Boyd) In this special ADA 2025 edition of Beyond the Bolus, host Nancy sits down with Kellee Miller and Jennifer Boyd from Insulet’s Medical Affairs team to discuss groundbreaking data on the Omnipod 5 Automated Insulin Delivery System in people with type 2 diabetes. From real-world evidence across 23,000+ users to insights on insulin dosing, quality of life, and optimized settings, this episode dives deep into how Omnipod 5 is transforming diabetes care. Whether you're a prescriber, educator, or caring for someone living with diabetes, this conversation offers valuable takeaways on the future of AID technology. Wed, 16 Jul 2025 09:06:00 -0000 full Insulet, Maker of Omnipod In this special ADA 2025 edition of Beyond the Bolus, host Nancy sits down with Kellee Miller and Jennifer Boyd from Insulet’s Medical Affairs team to discuss groundbreaking data on the Omnipod 5 Automated Insulin Delivery System in people with type 2 diabetes. From real-world evidence across 23,000+ users to insights on insulin dosing, quality of life, and optimized settings, this episode dives deep into how Omnipod 5 is transforming diabetes care. Whether you're a prescriber, educator, or caring for someone living with diabetes, this conversation offers valuable takeaways on the future of AID technology. In this special ADA 2025 edition of Beyond the Bolus, host Nancy sits down with Kellee Miller and Jennifer Boyd from Insulet’s Medical Affairs team to discuss groundbreaking data on the Omnipod 5 Automated Insulin Delivery System in people with type 2 diabetes. From real-world evidence across 23,000+ users to insights on insulin dosing, quality of life, and optimized settings, this episode dives deep into how Omnipod 5 is transforming diabetes care. Whether you're a prescriber, educator, or caring for someone living with diabetes, this conversation offers valuable takeaways on the future of AID technology.

]]> 853 Omnipod® 5 as your diabetes partner: support that adapts to you (featuring Dr. Eden Miller) How can AID systems like Omnipod 5 ease the mental burden on patients living with diabetes? To find out, Beyond the Bolus hosts Nancy Hanna and Dena Gottesman handed over hosting duties to our international colleague, Kate Neal, who was at ATTD in Amsterdam speaking with Dr. Eden Miller, a family practitioner, diabetologist, and co-founder of Diabetes Nation.    Dr. Miller shares her perspective (as both a healthcare provider and a person living with diabetes), explaining why she considers Omnipod 5 to be a “diabetes partner” – one that adapts and helps patients live more freely with less mental burden. They discuss how customizable glucose targets, setting adjustments, and the Custom Foods feature provide patients with a personalized and supportive experience.   Kate and Dr. Miller take a closer look at the SECURE-T2D study, which evaluated the use of Omnipod 5 in adults with type 2 diabetes. Dr. Miller outlines the key results and reflects on how the findings are already transforming her clinical practice.    You’ll also hear stories from Dr. Miller’s practice, such as a 78-year-old patient who was recently diagnosed with type 1 diabetes, and a 9-year-old who is learning independence - and managing type 1 diabetes – with the help of the Custom Foods feature. Dr. Miller  brings a practical, person-first approach to care, whether she’s breaking down barriers to technology, helping patients build confidence, or supporting them through the emotional side of diabetes. Thu, 19 Jun 2025 12:17:00 -0000 full Insulet, Maker of Omnipod How can AID systems like Omnipod 5 ease the mental burden on patients living with diabetes? To find out, Beyond the Bolus hosts Nancy Hanna and Dena Gottesman handed over hosting duties to our international colleague, Kate Neal, who was at ATTD in Amsterdam speaking with Dr. Eden Miller, a family practitioner, diabetologist, and co-founder of Diabetes Nation.    Dr. Miller shares her perspective (as both a healthcare provider and a person living with diabetes), explaining why she considers Omnipod 5 to be a “diabetes partner” – one that adapts and helps patients live more freely with less mental burden. They discuss how customizable glucose targets, setting adjustments, and the Custom Foods feature provide patients with a personalized and supportive experience.   Kate and Dr. Miller take a closer look at the SECURE-T2D study, which evaluated the use of Omnipod 5 in adults with type 2 diabetes. Dr. Miller outlines the key results and reflects on how the findings are already transforming her clinical practice.    You’ll also hear stories from Dr. Miller’s practice, such as a 78-year-old patient who was recently diagnosed with type 1 diabetes, and a 9-year-old who is learning independence - and managing type 1 diabetes – with the help of the Custom Foods feature. Dr. Miller  brings a practical, person-first approach to care, whether she’s breaking down barriers to technology, helping patients build confidence, or supporting them through the emotional side of diabetes. How can AID systems like Omnipod 5 ease the mental burden on patients living with diabetes? To find out, Beyond the Bolus hosts Nancy Hanna and Dena Gottesman handed over hosting duties to our international colleague, Kate Neal, who was at ATTD in Amsterdam speaking with Dr. Eden Miller, a family practitioner, diabetologist, and co-founder of Diabetes Nation. 

 

Dr. Miller shares her perspective (as both a healthcare provider and a person living with diabetes), explaining why she considers Omnipod 5 to be a “diabetes partner” – one that adapts and helps patients live more freely with less mental burden. They discuss how customizable glucose targets, setting adjustments, and the Custom Foods feature provide patients with a personalized and supportive experience.

 

Kate and Dr. Miller take a closer look at the SECURE-T2D study, which evaluated the use of Omnipod 5 in adults with type 2 diabetes. Dr. Miller outlines the key results and reflects on how the findings are already transforming her clinical practice. 

 

You’ll also hear stories from Dr. Miller’s practice, such as a 78-year-old patient who was recently diagnosed with type 1 diabetes, and a 9-year-old who is learning independence - and managing type 1 diabetes – with the help of the Custom Foods feature. Dr. Miller 

brings a practical, person-first approach to care, whether she’s breaking down barriers to technology, helping patients build confidence, or supporting them through the emotional side of diabetes.

]]> 2375 Digging into the SECURE T2D publication data: diverse patients, powerful outcomes The guest on this episode has an ongoing commercial relationship with Insulet, and Insulet has paid a fee for their participation in this podcast. In this episode, we dive into the SECURE T2D publication, with Dr. Chris Bajaj, an author and investigator in this groundbreaking study. Featuring a diverse population of participants with type 2 diabetes, the study revealed significant A1C reduction1, especially for those participants with baseline A1C above 9%. We also explore the simplified bolus strategies used to support patients, including those not carb counting at the start of the study. Tune in to learn how this research is shaping real-world diabetes care for people living with type 2 diabetes! 1. Pasquel FJ, et al. JAMA Network Open (2025). Prospective pivotal trial in 305 participants with T2D aged 18-75 yrs. Study included a 14-day standard therapy (ST) phase followed by a 13-week Omnipod 5 hybrid closed-loop phase. In a subgroup analysis of 68 participants with baseline A1c ≥ 9% Mean HbA1c: ST vs. 13-week Omnipod 5: 10.1% vs. 8.1%; (95% CI: -2.3%, -1.9%) Tue, 22 Apr 2025 11:57:00 -0000 full Insulet, Maker of Omnipod The guest on this episode has an ongoing commercial relationship with Insulet, and Insulet has paid a fee for their participation in this podcast. In this episode, we dive into the SECURE T2D publication, with Dr. Chris Bajaj, an author and investigator in this groundbreaking study. Featuring a diverse population of participants with type 2 diabetes, the study revealed significant A1C reduction1, especially for those participants with baseline A1C above 9%. We also explore the simplified bolus strategies used to support patients, including those not carb counting at the start of the study. Tune in to learn how this research is shaping real-world diabetes care for people living with type 2 diabetes! 1. Pasquel FJ, et al. JAMA Network Open (2025). Prospective pivotal trial in 305 participants with T2D aged 18-75 yrs. Study included a 14-day standard therapy (ST) phase followed by a 13-week Omnipod 5 hybrid closed-loop phase. In a subgroup analysis of 68 participants with baseline A1c ≥ 9% Mean HbA1c: ST vs. 13-week Omnipod 5: 10.1% vs. 8.1%; (95% CI: -2.3%, -1.9%) The guest on this episode has an ongoing commercial relationship with Insulet, and Insulet has paid a fee for their participation in this podcast.

In this episode, we dive into the SECURE T2D publication, with Dr. Chris Bajaj, an author and investigator in this groundbreaking study. Featuring a diverse population of participants with type 2 diabetes, the study revealed significant A1C reduction1, especially for those participants with baseline A1C above 9%. We also explore the simplified bolus strategies used to support patients, including those not carb counting at the start of the study. Tune in to learn how this research is shaping real-world diabetes care for people living with type 2 diabetes!


1. Pasquel FJ, et al. JAMA Network Open (2025). Prospective pivotal trial in 305 participants with T2D aged 18-75 yrs. Study included a 14-day standard therapy (ST) phase followed by a 13-week Omnipod 5 hybrid closed-loop phase. In a subgroup analysis of 68 participants with baseline A1c ≥ 9% Mean HbA1c: ST vs. 13-week Omnipod 5: 10.1% vs. 8.1%; (95% CI: -2.3%, -1.9%)

]]> 2077 Mind Over Diabetes: A Psychologist’s Take on the Freedom of Omnipod® 5 for iPhone (featuring Mark Heyman, PhD CDCES) The guest on this episode has an ongoing commercial relationship with Insulet, and Insulet has paid a fee for their participation in this podcast.   In this Beyond the Bolus episode, Mark Heyman, PhD CDCES, shares his experience using the Omnipod 5 App for iPhone as part of the limited market release (LMR). Dr. Heyman discusses this system's new features and how these have benefited his mental well-being and reduced his diabetes distress. Dive in to hear how the Omnipod 5 App for iPhone could help enhance your patient's diabetes management!  Tue, 29 Oct 2024 03:51:00 -0000 full Insulet, Maker of Omnipod The guest on this episode has an ongoing commercial relationship with Insulet, and Insulet has paid a fee for their participation in this podcast.   In this Beyond the Bolus episode, Mark Heyman, PhD CDCES, shares his experience using the Omnipod 5 App for iPhone as part of the limited market release (LMR). Dr. Heyman discusses this system's new features and how these have benefited his mental well-being and reduced his diabetes distress. Dive in to hear how the Omnipod 5 App for iPhone could help enhance your patient's diabetes management!  The guest on this episode has an ongoing commercial relationship with Insulet, and Insulet has paid a fee for their participation in this podcast.

 

In this Beyond the Bolus episode, Mark Heyman, PhD CDCES, shares his experience using the Omnipod 5 App for iPhone as part of the limited market release (LMR). Dr. Heyman discusses this system's new features and how these have benefited his mental well-being and reduced his diabetes distress. Dive in to hear how the Omnipod 5 App for iPhone could help enhance your patient's diabetes management! 

]]> 2304 Optimizing Omnipod® 5 for Better Patient Outcomes (featuring Jennifer Okemah MS, RDN, CSSD, BC-ADM, CDCES) The guest on this episode has an ongoing commercial relationship with Insulet, and Insulet has paid a fee for their participation in this podcast. Recorded Live at ADCES in New Orleans, Louisiana. In this episode, Jennifer Okemah joins us as we dive deep into SmartAdjust™ technology, the groundbreaking algorithm behind the Omnipod 5 Automated Insulin Delivery System. Jennifer breaks down how healthcare providers can fine-tune this innovative tool to better support patients with diabetes, ensuring more personalized insulin delivery to meet your patients’ individual needs. Discover actionable strategies to maximize the benefits of SmartAdjust™ technology, improve patient results, and enhance overall diabetes management.  Whether you’re a seasoned clinician or new to the Omnipod 5, this discussion offers valuable insights to help you get the most out of this cutting-edge technology. Tune in for expert tips and practical guidance! Wed, 23 Oct 2024 06:19:00 -0000 full Insulet, Maker of Omnipod The guest on this episode has an ongoing commercial relationship with Insulet, and Insulet has paid a fee for their participation in this podcast. Recorded Live at ADCES in New Orleans, Louisiana. In this episode, Jennifer Okemah joins us as we dive deep into SmartAdjust™ technology, the groundbreaking algorithm behind the Omnipod 5 Automated Insulin Delivery System. Jennifer breaks down how healthcare providers can fine-tune this innovative tool to better support patients with diabetes, ensuring more personalized insulin delivery to meet your patients’ individual needs. Discover actionable strategies to maximize the benefits of SmartAdjust™ technology, improve patient results, and enhance overall diabetes management.  Whether you’re a seasoned clinician or new to the Omnipod 5, this discussion offers valuable insights to help you get the most out of this cutting-edge technology. Tune in for expert tips and practical guidance! The guest on this episode has an ongoing commercial relationship with Insulet, and Insulet has paid a fee for their participation in this podcast.

Recorded Live at ADCES in New Orleans, Louisiana. In this episode, Jennifer Okemah joins us as we dive deep into SmartAdjust™ technology, the groundbreaking algorithm behind the Omnipod 5 Automated Insulin Delivery System. Jennifer breaks down how healthcare providers can fine-tune this innovative tool to better support patients with diabetes, ensuring more personalized insulin delivery to meet your patients’ individual needs. Discover actionable strategies to maximize the benefits of SmartAdjust™ technology, improve patient results, and enhance overall diabetes management. 

Whether you’re a seasoned clinician or new to the Omnipod 5, this discussion offers valuable insights to help you get the most out of this cutting-edge technology. Tune in for expert tips and practical guidance!

]]> 1810 Unlock the Future of Type 2 Diabetes Care with Dr. Viral Shah Recorded Live at ADCES in New Orleans, Louisiana. Dive into the groundbreaking SECURE T2D study, the largest and most diverse trial ever conducted on Automated Insulin Delivery (AID) for people with type 2 diabetes. Discover how Omnipod 5 demonstrated improvements in A1C levels, increased time in range (TIR), and participant-reported reduction in Diabetes Distress. Dr. Viral Shah from the Indiana University School of Medicine, and an investigator in this trial, reveals key insights on how Omnipod 5 can help simplify diabetes management. Don’t miss this chance to learn how Omnipod 5 can enhance your care for your patients living with type 2 diabetes. ------------ Dr. Viral Shah is an endocrinologist. Dr. Shah has an ongoing commercial relationship with Insulet and Insulet has paid him a fee to participate in this podcast. The opinions and views expressed in this podcast are his own. Wed, 11 Sep 2024 04:51:00 -0000 full Insulet, Maker of Omnipod Recorded Live at ADCES in New Orleans, Louisiana. Dive into the groundbreaking SECURE T2D study, the largest and most diverse trial ever conducted on Automated Insulin Delivery (AID) for people with type 2 diabetes. Discover how Omnipod 5 demonstrated improvements in A1C levels, increased time in range (TIR), and participant-reported reduction in Diabetes Distress. Dr. Viral Shah from the Indiana University School of Medicine, and an investigator in this trial, reveals key insights on how Omnipod 5 can help simplify diabetes management. Don’t miss this chance to learn how Omnipod 5 can enhance your care for your patients living with type 2 diabetes. ------------ Dr. Viral Shah is an endocrinologist. Dr. Shah has an ongoing commercial relationship with Insulet and Insulet has paid him a fee to participate in this podcast. The opinions and views expressed in this podcast are his own. Recorded Live at ADCES in New Orleans, Louisiana.


Dive into the groundbreaking SECURE T2D study, the largest and most diverse trial ever conducted on Automated Insulin Delivery (AID) for people with type 2 diabetes.


Discover how Omnipod 5 demonstrated improvements in A1C levels, increased time in range (TIR), and participant-reported reduction in Diabetes Distress. Dr. Viral Shah from the Indiana University School of Medicine, and an investigator in this trial, reveals key insights on how Omnipod 5 can help simplify diabetes management.


Don’t miss this chance to learn how Omnipod 5 can enhance your care for your patients living with type 2 diabetes.


------------


Dr. Viral Shah is an endocrinologist. Dr. Shah has an ongoing commercial relationship with Insulet and Insulet has paid him a fee to participate in this podcast. The opinions and views expressed in this podcast are his own.

]]> 967 The Power of the Pod Recorded live at the ADA Conference in Orlando, Florida. Dive into the future of diabetes management with Eric Benjamin, Insulet’s Chief Product & Customer Experience Officer. In this episode, Eric reveals the innovative journey behind Omnipod, highlighting our relentless focus on customer needs and top-tier performance with every Pod change. Discover how we're revolutionizing Automated Insulin Delivery with our wearable, tubeless Pod, and learn how these advancements simplify life for people with diabetes. Don't miss this insider's perspective on transforming care through cutting-edge technology. ------------ Eric Benjamin is an employee of Insulet Corporation. The opinions shared in the podcast are his own. Tue, 27 Aug 2024 14:33:00 -0000 full Insulet, Maker of Omnipod Recorded live at the ADA Conference in Orlando, Florida. Dive into the future of diabetes management with Eric Benjamin, Insulet’s Chief Product & Customer Experience Officer. In this episode, Eric reveals the innovative journey behind Omnipod, highlighting our relentless focus on customer needs and top-tier performance with every Pod change. Discover how we're revolutionizing Automated Insulin Delivery with our wearable, tubeless Pod, and learn how these advancements simplify life for people with diabetes. Don't miss this insider's perspective on transforming care through cutting-edge technology. ------------ Eric Benjamin is an employee of Insulet Corporation. The opinions shared in the podcast are his own. Recorded live at the ADA Conference in Orlando, Florida.


Dive into the future of diabetes management with Eric Benjamin, Insulet’s Chief Product & Customer Experience Officer. In this episode, Eric reveals the innovative journey behind Omnipod, highlighting our relentless focus on customer needs and top-tier performance with every Pod change.


Discover how we're revolutionizing Automated Insulin Delivery with our wearable, tubeless Pod, and learn how these advancements simplify life for people with diabetes. Don't miss this insider's perspective on transforming care through cutting-edge technology.


------------


Eric Benjamin is an employee of Insulet Corporation. The opinions shared in the podcast are his own.

]]> 987 Challenging AID Candidacy Norms Recorded live at the ADA Conference in Orlando, Florida 2024. Nancy Hanna is joined by Cari Berget MPH, RN, CDCES who is a Research Instructor of Pediatric Endocrinology at the University of Colorado School of Medicine – Barbara Davis Center. During this episode, Nancy and Cari discuss automated insulin delivery (AID) candidacy and challenge the perception that people need to meet certain requirements to be considered for AID. Cari shares her experience prescribing diabetes technology to patients who typically might not been considered for automated insulin delivery and shows the progress and clinical benefits that some of her patients have experienced on Omnipod 5.   ------------ Cari Berget, MPH is a Registered Nurse (RN) and a Certified Diabetes Care and Education Specialist (CDCES). Cari Berget has an ongoing commercial relationship with Insulet and Insulet has paid her a fee to participate in this podcast. The opinions and views expressed in this podcast are her own. Mon, 19 Aug 2024 09:30:00 -0000 full Insulet, Maker of Omnipod Recorded live at the ADA Conference in Orlando, Florida 2024. Nancy Hanna is joined by Cari Berget MPH, RN, CDCES who is a Research Instructor of Pediatric Endocrinology at the University of Colorado School of Medicine – Barbara Davis Center. During this episode, Nancy and Cari discuss automated insulin delivery (AID) candidacy and challenge the perception that people need to meet certain requirements to be considered for AID. Cari shares her experience prescribing diabetes technology to patients who typically might not been considered for automated insulin delivery and shows the progress and clinical benefits that some of her patients have experienced on Omnipod 5.   ------------ Cari Berget, MPH is a Registered Nurse (RN) and a Certified Diabetes Care and Education Specialist (CDCES). Cari Berget has an ongoing commercial relationship with Insulet and Insulet has paid her a fee to participate in this podcast. The opinions and views expressed in this podcast are her own. Recorded live at the ADA Conference in Orlando, Florida 2024.

Nancy Hanna is joined by Cari Berget MPH, RN, CDCES who is a Research Instructor of Pediatric Endocrinology at the University of Colorado School of Medicine – Barbara Davis Center. During this episode, Nancy and Cari discuss automated insulin delivery (AID) candidacy and challenge the perception that people need to meet certain requirements to be considered for AID.

Cari shares her experience prescribing diabetes technology to patients who typically might not been considered for automated insulin delivery and shows the progress and clinical benefits that some of her patients have experienced on Omnipod 5.  

------------

Cari Berget, MPH is a Registered Nurse (RN) and a Certified Diabetes Care and Education Specialist (CDCES). Cari Berget has an ongoing commercial relationship with Insulet and Insulet has paid her a fee to participate in this podcast. The opinions and views expressed in this podcast are her own.

]]> 1607 Omnipod 5 with Dexcom G7 Integration is Here! Recorded live at the ADA Conference in Orlando, Florida. Nancy Hanna is joined by Dr. Pablo Mora who is an Endocrinologist at the North Texas Diabetes & Endocrinology Medical Center in Plano, Texas. During this episode, Nancy and Dr. Mora discuss the integration between the Omnipod 5 Automated Insulin Delivery System and the Dexcom G7 CGM. Dr. Mora discusses his experience as part of the Limited Market Release for Omnipod 5 with Dexcom G7 and provides insights into the benefit of this integration for his patients with type 1 diabetes. Listen to learn how Dr. Mora has leveraged this technology to simplify diabetes management with his patients!  ------------ Dr. Pablo Mora is an endocrinologist. Dr. Mora has an ongoing commercial relationship with Insulet and Insulet has paid him a fee to participate in this podcast. The opinions and views expressed in this podcast are his own. Mon, 19 Aug 2024 09:30:00 -0000 full Insulet, Maker of Omnipod Recorded live at the ADA Conference in Orlando, Florida. Nancy Hanna is joined by Dr. Pablo Mora who is an Endocrinologist at the North Texas Diabetes & Endocrinology Medical Center in Plano, Texas. During this episode, Nancy and Dr. Mora discuss the integration between the Omnipod 5 Automated Insulin Delivery System and the Dexcom G7 CGM. Dr. Mora discusses his experience as part of the Limited Market Release for Omnipod 5 with Dexcom G7 and provides insights into the benefit of this integration for his patients with type 1 diabetes. Listen to learn how Dr. Mora has leveraged this technology to simplify diabetes management with his patients!  ------------ Dr. Pablo Mora is an endocrinologist. Dr. Mora has an ongoing commercial relationship with Insulet and Insulet has paid him a fee to participate in this podcast. The opinions and views expressed in this podcast are his own. Recorded live at the ADA Conference in Orlando, Florida.

Nancy Hanna is joined by Dr. Pablo Mora who is an Endocrinologist at the North Texas Diabetes & Endocrinology Medical Center in Plano, Texas. During this episode, Nancy and Dr. Mora discuss the integration between the Omnipod 5 Automated Insulin Delivery System and the Dexcom G7 CGM.

Dr. Mora discusses his experience as part of the Limited Market Release for Omnipod 5 with Dexcom G7 and provides insights into the benefit of this integration for his patients with type 1 diabetes.

Listen to learn how Dr. Mora has leveraged this technology to simplify diabetes management with his patients! 

------------

Dr. Pablo Mora is an endocrinologist. Dr. Mora has an ongoing commercial relationship with Insulet and Insulet has paid him a fee to participate in this podcast. The opinions and views expressed in this podcast are his own.

]]> 1414 Omnipod 5 Real-World Evidence Data: A Deep Dive Recorded live at the ADA Conference in Orlando, Florida. Nancy Hanna is joined by Dr. Greg Forlenza who is an Endocrinologist at the University of Colorado School of Medicine – Barbara Davis Center. Dr. Forlenza is the lead author of a publication in the Diabetes Technology & Therapeutics in which the use of the Omnipod 5 Automated Insulin Delivery System was analyzed in almost 70,000 people with type 1 diabetes. Nancy and Dr. Forlenza discuss the relevance of real-world evidence from a diverse group of patients and how that translates into actual practice. Learn how Omnipod 5 has performed in real-world settings, and why having this data can help personalize diabetes care by understanding how different patient demographics can benefit from tubeless AID technology.  ------------ Dr. Greg Forlenza is an endocrinologist. Dr. Forlenza has an ongoing commercial relationship with Insulet and Insulet has paid him a fee to participate in this podcast. The opinions and views expressed in this podcast are his own. Mon, 19 Aug 2024 05:00:00 -0000 full Insulet, Maker of Omnipod Recorded live at the ADA Conference in Orlando, Florida. Nancy Hanna is joined by Dr. Greg Forlenza who is an Endocrinologist at the University of Colorado School of Medicine – Barbara Davis Center. Dr. Forlenza is the lead author of a publication in the Diabetes Technology & Therapeutics in which the use of the Omnipod 5 Automated Insulin Delivery System was analyzed in almost 70,000 people with type 1 diabetes. Nancy and Dr. Forlenza discuss the relevance of real-world evidence from a diverse group of patients and how that translates into actual practice. Learn how Omnipod 5 has performed in real-world settings, and why having this data can help personalize diabetes care by understanding how different patient demographics can benefit from tubeless AID technology.  ------------ Dr. Greg Forlenza is an endocrinologist. Dr. Forlenza has an ongoing commercial relationship with Insulet and Insulet has paid him a fee to participate in this podcast. The opinions and views expressed in this podcast are his own. Recorded live at the ADA Conference in Orlando, Florida.


Nancy Hanna is joined by Dr. Greg Forlenza who is an Endocrinologist at the University of Colorado School of Medicine – Barbara Davis Center. Dr. Forlenza is the lead author of a publication in the Diabetes Technology & Therapeutics in which the use of the Omnipod 5 Automated Insulin Delivery System was analyzed in almost 70,000 people with type 1 diabetes.


Nancy and Dr. Forlenza discuss the relevance of real-world evidence from a diverse group of patients and how that translates into actual practice. Learn how Omnipod 5 has performed in real-world settings, and why having this data can help personalize diabetes care by understanding how different patient demographics can benefit from tubeless AID technology. 


------------


Dr. Greg Forlenza is an endocrinologist. Dr. Forlenza has an ongoing commercial relationship with Insulet and Insulet has paid him a fee to participate in this podcast. The opinions and views expressed in this podcast are his own.

]]> 2173 Diabetes Distress with Dr. William Polonsky Recorded live at the ADCES Conference in Houston, Nancy Hanna and Dena Gottesman are joined by Dr. William Polonsky. Dr. Polonsky is the founder and president of the Behavioral Diabetes Institute, an organization dedicated to studying the unmet psychological needs of people living with diabetes. He’s also an Associate Clinical Professor at the University of California in San Diego. Highlights include:• Where to find the best lactose-free ice cream in the universe!• Dr. Polonsky’s golden nugget for new diabetes educators. • The one question you should ask all your patients at every visit. • How the world’s first behavioral diabetes institute was formed. • The origin and meaning of the term “Diabetes Distress” and strategies to communicate effectively with patients and ease burden• Psychosocial outcomes with Omnipod 5 and impact on caregivers Dr. William Polonsky has an ongoing commercial relationship with Insulet and Insulet has paid him a fee to participate in the making of this podcast. The opinions and views expressed in this podcast are his own.Please speak with your Healthcare team before making any changes to your diabetes management. This podcast provides general information and discussions about health and related subjects. This information and other content provided in this podcast, or in any linked materials, are not intended and should not be construed as medical advice, nor is the information a substitute for professional medical expertise or treatment. If you or any other person has a medical concern, you should consult your health care provider or seek other professional medical treatment. Never disregard professional medical advice or delay in seeking it because of something that you have heard in this podcast or read in any linked materials. The opinions and views expressed on this podcast and website have no relation to those of any academic, hospital, health practice or other institution. **Please consult the Omnipod® 5 Automated Insulin Delivery System User Guide for more information. Mon, 06 Nov 2023 08:21:00 -0000 full Insulet, Maker of Omnipod Recorded live at the ADCES Conference in Houston, Nancy Hanna and Dena Gottesman are joined by Dr. William Polonsky. Dr. Polonsky is the founder and president of the Behavioral Diabetes Institute, an organization dedicated to studying the unmet psychological needs of people living with diabetes. He’s also an Associate Clinical Professor at the University of California in San Diego. Highlights include:• Where to find the best lactose-free ice cream in the universe!• Dr. Polonsky’s golden nugget for new diabetes educators. • The one question you should ask all your patients at every visit. • How the world’s first behavioral diabetes institute was formed. • The origin and meaning of the term “Diabetes Distress” and strategies to communicate effectively with patients and ease burden• Psychosocial outcomes with Omnipod 5 and impact on caregivers Dr. William Polonsky has an ongoing commercial relationship with Insulet and Insulet has paid him a fee to participate in the making of this podcast. The opinions and views expressed in this podcast are his own.Please speak with your Healthcare team before making any changes to your diabetes management. This podcast provides general information and discussions about health and related subjects. This information and other content provided in this podcast, or in any linked materials, are not intended and should not be construed as medical advice, nor is the information a substitute for professional medical expertise or treatment. If you or any other person has a medical concern, you should consult your health care provider or seek other professional medical treatment. Never disregard professional medical advice or delay in seeking it because of something that you have heard in this podcast or read in any linked materials. The opinions and views expressed on this podcast and website have no relation to those of any academic, hospital, health practice or other institution. **Please consult the Omnipod® 5 Automated Insulin Delivery System User Guide for more information.
Highlights include:
• Where to find the best lactose-free ice cream in the universe!
• Dr. Polonsky’s golden nugget for new diabetes educators. 
• The one question you should ask all your patients at every visit. 
• How the world’s first behavioral diabetes institute was formed. 
• The origin and meaning of the term “Diabetes Distress” and strategies to communicate effectively with patients and ease burden
• Psychosocial outcomes with Omnipod 5 and impact on caregivers 

Dr. William Polonsky has an ongoing commercial relationship with Insulet and Insulet has paid him a fee to participate in the making of this podcast. The opinions and views expressed in this podcast are his own.


Please speak with your Healthcare team before making any changes to your diabetes management. This podcast provides general information and discussions about health and related subjects. This information and other content provided in this podcast, or in any linked materials, are not intended and should not be construed as medical advice, nor is the information a substitute for professional medical expertise or treatment. If you or any other person has a medical concern, you should consult your health care provider or seek other professional medical treatment. Never disregard professional medical advice or delay in seeking it because of something that you have heard in this podcast or read in any linked materials. The opinions and views expressed on this podcast and website have no relation to those of any academic, hospital, health practice or other institution. **Please consult the Omnipod® 5 Automated Insulin Delivery System User Guide for more information.

]]> 2316 Celebrating 50 years of Advancing Diabetes Care & Education This special episode is a compilation of conversations from the Association of Diabetes Care & Education Specialists (ADCES) 2023 conference in Houston. Joining Nancy on day 2 of the conference were a few very special guests. Alissa Heizler-Mendoza, a registered dietitian and certified diabetes care and education specialist dropped by the studio to discuss her role of leading the advocacy and government affairs team at Insulet. She empowers us to elevate our voices to influence change and help more people living with diabetes access life-changing technology.Sarah Yourman-Tota also stopped by to chat with Nancy about her work in pediatric endocrinology, and the positive impact technology can have for caregivers.   Nancy was also joined by Jennifer Boyd, medical science liaison at Insulet. Jenn discusses some patient success stories from one year of Omnipod 5.Lastly, Nancy and Dena are joined by Dr. Diana Isaacs and Natalie Bellini to discuss common misconceptions people have about different AID systems. Diana Isaacs and Natalie Bellini have an ongoing commercial relationship with Insulet.Each guest’s views and opinions are their own and not those of Insulet.Please speak with your Healthcare team before making any changes to your diabetes management. This podcast provides general information and discussions about health and related subjects. This information and other content provided in this podcast, or in any linked materials, are not intended and should not be construed as medical advice, nor is the information a substitute for professional medical expertise or treatment. If you or any other person has a medical concern, you should consult your health care provider or seek other professional medical treatment. Never disregard professional medical advice or delay in seeking it because of something that you have heard in this podcast or read in any linked materials. The opinions and views expressed on this podcast and website have no relation to those of any academic, hospital, health practice or other institution. **Please consult the Omnipod® 5 Automated Insulin Delivery System User Guide for more information. Mon, 09 Oct 2023 12:09:00 -0000 full Insulet, Maker of Omnipod This special episode is a compilation of conversations from the Association of Diabetes Care & Education Specialists (ADCES) 2023 conference in Houston. Joining Nancy on day 2 of the conference were a few very special guests. Alissa Heizler-Mendoza, a registered dietitian and certified diabetes care and education specialist dropped by the studio to discuss her role of leading the advocacy and government affairs team at Insulet. She empowers us to elevate our voices to influence change and help more people living with diabetes access life-changing technology.Sarah Yourman-Tota also stopped by to chat with Nancy about her work in pediatric endocrinology, and the positive impact technology can have for caregivers.   Nancy was also joined by Jennifer Boyd, medical science liaison at Insulet. Jenn discusses some patient success stories from one year of Omnipod 5.Lastly, Nancy and Dena are joined by Dr. Diana Isaacs and Natalie Bellini to discuss common misconceptions people have about different AID systems. Diana Isaacs and Natalie Bellini have an ongoing commercial relationship with Insulet.Each guest’s views and opinions are their own and not those of Insulet.Please speak with your Healthcare team before making any changes to your diabetes management. This podcast provides general information and discussions about health and related subjects. This information and other content provided in this podcast, or in any linked materials, are not intended and should not be construed as medical advice, nor is the information a substitute for professional medical expertise or treatment. If you or any other person has a medical concern, you should consult your health care provider or seek other professional medical treatment. Never disregard professional medical advice or delay in seeking it because of something that you have heard in this podcast or read in any linked materials. The opinions and views expressed on this podcast and website have no relation to those of any academic, hospital, health practice or other institution. **Please consult the Omnipod® 5 Automated Insulin Delivery System User Guide for more information.
Joining Nancy on day 2 of the conference were a few very special guests. Alissa Heizler-Mendoza, a registered dietitian and certified diabetes care and education specialist dropped by the studio to discuss her role of leading the advocacy and government affairs team at Insulet. She empowers us to elevate our voices to influence change and help more people living with diabetes access life-changing technology.

Sarah Yourman-Tota also stopped by to chat with Nancy about her work in pediatric endocrinology, and the positive impact technology can have for caregivers.   

Nancy was also joined by Jennifer Boyd, medical science liaison at Insulet. Jenn discusses some patient success stories from one year of Omnipod 5.

Lastly, Nancy and Dena are joined by Dr. Diana Isaacs and Natalie Bellini to discuss common misconceptions people have about different AID systems. Diana Isaacs and Natalie Bellini have an ongoing commercial relationship with Insulet.

Each guest’s views and opinions are their own and not those of Insulet.

Please speak with your Healthcare team before making any changes to your diabetes management. This podcast provides general information and discussions about health and related subjects. This information and other content provided in this podcast, or in any linked materials, are not intended and should not be construed as medical advice, nor is the information a substitute for professional medical expertise or treatment. If you or any other person has a medical concern, you should consult your health care provider or seek other professional medical treatment. Never disregard professional medical advice or delay in seeking it because of something that you have heard in this podcast or read in any linked materials. The opinions and views expressed on this podcast and website have no relation to those of any academic, hospital, health practice or other institution. **Please consult the Omnipod® 5 Automated Insulin Delivery System User Guide for more information.]]> 1849 A Dynamic Duo: Omnipod & Dexcom Join us for an insightful journey into the world of diabetes management technology on this very special episode of Beyond The Bolus. Recorded live from the American Diabetes Association’s 83rd Scientific Sessions in San Diego, host Nancy Hanna is joined by Dexcom’s Cher Pastore in our very first simulcast.  To explore how Omnipod and Dexcom are influencing the dynamics of diabetes technology and reshaping patient outcomes for the better, they’re joined by Dr. Viral Shah - an endocrinologist whose research into these innovative therapies has touched and improved countless lives. During the episode, you'll discover how technological advancements are changing the game and reducing daily management burdens for people with diabetes. Hear invaluable insights from Dr. Shah on the importance of early adoption of tools such as CGM and the Omnipod 5, and how they can prove pivotal in managing diabetes and improving glycemic control. Dr. Shah examines the different barriers to technology adoption, and how fostering a pro-active conversation can help overcome them. All this, plus a sneak peek into the future of diabetes tech.Please speak with your Healthcare team before making any changes to your diabetes management.  This podcast provides general information and discussions about health and related subjects. This information and other content provided in this podcast, or in any linked materials, are not intended and should not be construed as medical advice, nor is the information a substitute for professional medical expertise or treatment. If you or any other person has a medical concern, you should consult your health care provider or seek other professional medical treatment. Never disregard professional medical advice or delay in seeking it because of something that you have heard in this podcast or read in any linked materials. The opinions and views expressed on this podcast and website have no relation to those of any academic, hospital, health practice or other institution.  **Please consult the Omnipod® 5 Automated Insulin Delivery System User Guide for more information. Cited resources:1 Champakanath A, et al. Continuous Glucose Monitoring Initiation Within First Year of Type 1 Diabetes Diagnosis Is Associated With Improved Glycemic Outcomes: 7-Year Follow-Up Study. Diabetes Care. 2022;45(3):750-753.2 Brown SA, et al. Multicenter Trial of a Tubeless, On-Body Automated Insulin Delivery System With Customizable Glycemic Targets in Pediatric and Adult Participants With Type 1 Diabetes. Diabetes Care. 2021;44(7):1630-1640. Thu, 10 Aug 2023 14:50:00 -0000 full Insulet, Maker of Omnipod Join us for an insightful journey into the world of diabetes management technology on this very special episode of Beyond The Bolus. Recorded live from the American Diabetes Association’s 83rd Scientific Sessions in San Diego, host Nancy Hanna is joined by Dexcom’s Cher Pastore in our very first simulcast.  To explore how Omnipod and Dexcom are influencing the dynamics of diabetes technology and reshaping patient outcomes for the better, they’re joined by Dr. Viral Shah - an endocrinologist whose research into these innovative therapies has touched and improved countless lives. During the episode, you'll discover how technological advancements are changing the game and reducing daily management burdens for people with diabetes. Hear invaluable insights from Dr. Shah on the importance of early adoption of tools such as CGM and the Omnipod 5, and how they can prove pivotal in managing diabetes and improving glycemic control. Dr. Shah examines the different barriers to technology adoption, and how fostering a pro-active conversation can help overcome them. All this, plus a sneak peek into the future of diabetes tech.Please speak with your Healthcare team before making any changes to your diabetes management.  This podcast provides general information and discussions about health and related subjects. This information and other content provided in this podcast, or in any linked materials, are not intended and should not be construed as medical advice, nor is the information a substitute for professional medical expertise or treatment. If you or any other person has a medical concern, you should consult your health care provider or seek other professional medical treatment. Never disregard professional medical advice or delay in seeking it because of something that you have heard in this podcast or read in any linked materials. The opinions and views expressed on this podcast and website have no relation to those of any academic, hospital, health practice or other institution.  **Please consult the Omnipod® 5 Automated Insulin Delivery System User Guide for more information. Cited resources:1 Champakanath A, et al. Continuous Glucose Monitoring Initiation Within First Year of Type 1 Diabetes Diagnosis Is Associated With Improved Glycemic Outcomes: 7-Year Follow-Up Study. Diabetes Care. 2022;45(3):750-753.2 Brown SA, et al. Multicenter Trial of a Tubeless, On-Body Automated Insulin Delivery System With Customizable Glycemic Targets in Pediatric and Adult Participants With Type 1 Diabetes. Diabetes Care. 2021;44(7):1630-1640. Beyond The Bolus. Recorded live from the American Diabetes Association’s 83rd Scientific Sessions in San Diego, host Nancy Hanna is joined by Dexcom’s Cher Pastore in our very first simulcast.  To explore how Omnipod and Dexcom are influencing the dynamics of diabetes technology and reshaping patient outcomes for the better, they’re joined by Dr. Viral Shah - an endocrinologist whose research into these innovative therapies has touched and improved countless lives. During the episode, you'll discover how technological advancements are changing the game and reducing daily management burdens for people with diabetes. Hear invaluable insights from Dr. Shah on the importance of early adoption of tools such as CGM and the Omnipod 5, and how they can prove pivotal in managing diabetes and improving glycemic control. Dr. Shah examines the different barriers to technology adoption, and how fostering a pro-active conversation can help overcome them. All this, plus a sneak peek into the future of diabetes tech.

Please speak with your Healthcare team before making any changes to your diabetes management. 
This podcast provides general information and discussions about health and related subjects. This information and other content provided in this podcast, or in any linked materials, are not intended and should not be construed as medical advice, nor is the information a substitute for professional medical expertise or treatment. If you or any other person has a medical concern, you should consult your health care provider or seek other professional medical treatment. Never disregard professional medical advice or delay in seeking it because of something that you have heard in this podcast or read in any linked materials. The opinions and views expressed on this podcast and website have no relation to those of any academic, hospital, health practice or other institution. 

**Please consult the Omnipod® 5 Automated Insulin Delivery System User Guide for more information.

Cited resources:
1 Champakanath A, et al. Continuous Glucose Monitoring Initiation Within First Year of Type 1 Diabetes Diagnosis Is Associated With Improved Glycemic Outcomes: 7-Year Follow-Up Study. Diabetes Care. 2022;45(3):750-753.2 Brown SA, et al. Multicenter Trial of a Tubeless, On-Body Automated Insulin Delivery System With Customizable Glycemic Targets in Pediatric and Adult Participants With Type 1 Diabetes. Diabetes Care. 2021;44(7):1630-1640.]]> 2263 Teenage Transitions Insulet and Beyond The Bolus are back at the ADA Scientific Sessions. Nancy Hanna, Clinical Services Manager at Insulet, is joined by Dr. Anita Swamy for a special live podcast, recording at the Omnipod booth in San Diego. Join them on a truly enlightening journey into the world of diabetes management as seen through the lens of the latest technology. The Omnipod 5 system offers an optimistic approach towards alleviating the daily challenges associated with managing diabetes.  Dr. Swamy is a stalwart in diabetes management, and she delivers a masterclass for the listeners on integrating technology into patient care.Dr. Swamy presents in-depth knowledge of both types of diabetes and their unique needs. She pinpoints how innovative methods such as the Automated Insulin Delivery (AID) can result in a marked improvement in patient care while minimizing disease management-associated stress. Furthermore, the episode addresses low-resource demographics' ability to utilize such technology, breaking common misconceptions. Additionally, with a keen focus on patients transitioning from pediatrics to adult care, Dr. Swamy shares strategies to empower these patients in managing their disease independently.Please speak with your Healthcare team before making any changes to your diabetes management. This podcast provides general information and discussions about health and related subjects. This information and other content provided in this podcast, or in any linked materials, are not intended and should not be construed as medical advice, nor is the information a substitute for professional medical expertise or treatment. If you or any other person has a medical concern, you should consult your health care provider or seek other professional medical treatment. Never disregard professional medical advice or delay in seeking it because of something that you have heard in this podcast or read in any linked materials. The opinions and views expressed on this podcast and website have no relation to those of any academic, hospital, health practice or other institution. **Please consult the Omnipod® 5 Automated Insulin Delivery System User Guide for more information. Thu, 10 Aug 2023 14:47:00 -0000 full Insulet, Maker of Omnipod Insulet and Beyond The Bolus are back at the ADA Scientific Sessions. Nancy Hanna, Clinical Services Manager at Insulet, is joined by Dr. Anita Swamy for a special live podcast, recording at the Omnipod booth in San Diego. Join them on a truly enlightening journey into the world of diabetes management as seen through the lens of the latest technology. The Omnipod 5 system offers an optimistic approach towards alleviating the daily challenges associated with managing diabetes.  Dr. Swamy is a stalwart in diabetes management, and she delivers a masterclass for the listeners on integrating technology into patient care.Dr. Swamy presents in-depth knowledge of both types of diabetes and their unique needs. She pinpoints how innovative methods such as the Automated Insulin Delivery (AID) can result in a marked improvement in patient care while minimizing disease management-associated stress. Furthermore, the episode addresses low-resource demographics' ability to utilize such technology, breaking common misconceptions. Additionally, with a keen focus on patients transitioning from pediatrics to adult care, Dr. Swamy shares strategies to empower these patients in managing their disease independently.Please speak with your Healthcare team before making any changes to your diabetes management. This podcast provides general information and discussions about health and related subjects. This information and other content provided in this podcast, or in any linked materials, are not intended and should not be construed as medical advice, nor is the information a substitute for professional medical expertise or treatment. If you or any other person has a medical concern, you should consult your health care provider or seek other professional medical treatment. Never disregard professional medical advice or delay in seeking it because of something that you have heard in this podcast or read in any linked materials. The opinions and views expressed on this podcast and website have no relation to those of any academic, hospital, health practice or other institution. **Please consult the Omnipod® 5 Automated Insulin Delivery System User Guide for more information.
Join them on a truly enlightening journey into the world of diabetes management as seen through the lens of the latest technology. The Omnipod 5 system offers an optimistic approach towards alleviating the daily challenges associated with managing diabetes. 
 
Dr. Swamy is a stalwart in diabetes management, and she delivers a masterclass for the listeners on integrating technology into patient care.

Dr. Swamy presents in-depth knowledge of both types of diabetes and their unique needs. She pinpoints how innovative methods such as the Automated Insulin Delivery (AID) can result in a marked improvement in patient care while minimizing disease management-associated stress. 
Furthermore, the episode addresses low-resource demographics' ability to utilize such technology, breaking common misconceptions. Additionally, with a keen focus on patients transitioning from pediatrics to adult care, Dr. Swamy shares strategies to empower these patients in managing their disease independently.


Please speak with your Healthcare team before making any changes to your diabetes management. 
This podcast provides general information and discussions about health and related subjects. This information and other content provided in this podcast, or in any linked materials, are not intended and should not be construed as medical advice, nor is the information a substitute for professional medical expertise or treatment. If you or any other person has a medical concern, you should consult your health care provider or seek other professional medical treatment. Never disregard professional medical advice or delay in seeking it because of something that you have heard in this podcast or read in any linked materials. The opinions and views expressed on this podcast and website have no relation to those of any academic, hospital, health practice or other institution. 

**Please consult the Omnipod® 5 Automated Insulin Delivery System User Guide for more information.]]> 1954 Omnipod® 5 Automated Insulin Delivery System: Facts vs. Fake News Part 2 Nancy Hanna RN, BSN, CDCES and Dena Gottesman MS, RD, CDCES are joined by Leslie Barrett MS, RD, CDCES to clear up common misconceptions about the Omnipod® 5 Automated Insulin Delivery System. Leslie has been working on Omnipod® 5 since the development from user experience and design to clinical trial site training and support. In part 2 of this fact from fake news episode she will share more details on the Omnipod 5 algorithm known as SmartAdjust™ technology and best practices for everyday use and optimization. Questions covered in this episode:• What are the requirements for entering Automated Mode?• What are the considerations for transitioning from different therapies?• How often should users deliver correction boluses?• What are the adjustable settings for Omnipod 5, and what does and does not impact algorithm behavior?  Please speak with your healthcare team before making any changes to your diabetes management. This podcast provides general information and discussions about health and related subjects. This information and other content provided in this podcast, or in any linked materials, are not intended and should not be construed as medical advice, nor is the information a substitute for professional medical expertise or treatment. If you or any other person has a medical concern, you should consult your health care provider or seek other professional medical treatment. Never disregard professional medical advice or delay in seeking it because of something that you have heard in this podcast or read in any linked materials. The opinions and views expressed on this podcast and website have no relation to those of any academic, hospital, health practice or other institution. **Please consult the Omnipod® 5 Automated Insulin Delivery System User Guide for more information. Thu, 15 Dec 2022 08:24:00 -0000 full Insulet, Maker of Omnipod Nancy Hanna RN, BSN, CDCES and Dena Gottesman MS, RD, CDCES are joined by Leslie Barrett MS, RD, CDCES to clear up common misconceptions about the Omnipod® 5 Automated Insulin Delivery System. Leslie has been working on Omnipod® 5 since the development from user experience and design to clinical trial site training and support. In part 2 of this fact from fake news episode she will share more details on the Omnipod 5 algorithm known as SmartAdjust™ technology and best practices for everyday use and optimization. Questions covered in this episode:• What are the requirements for entering Automated Mode?• What are the considerations for transitioning from different therapies?• How often should users deliver correction boluses?• What are the adjustable settings for Omnipod 5, and what does and does not impact algorithm behavior?  Please speak with your healthcare team before making any changes to your diabetes management. This podcast provides general information and discussions about health and related subjects. This information and other content provided in this podcast, or in any linked materials, are not intended and should not be construed as medical advice, nor is the information a substitute for professional medical expertise or treatment. If you or any other person has a medical concern, you should consult your health care provider or seek other professional medical treatment. Never disregard professional medical advice or delay in seeking it because of something that you have heard in this podcast or read in any linked materials. The opinions and views expressed on this podcast and website have no relation to those of any academic, hospital, health practice or other institution. **Please consult the Omnipod® 5 Automated Insulin Delivery System User Guide for more information.
Questions covered in this episode:

• What are the requirements for entering Automated Mode?
• What are the considerations for transitioning from different therapies?
• How often should users deliver correction boluses?
• What are the adjustable settings for Omnipod 5, and what does and does not impact algorithm behavior?  

Please speak with your healthcare team before making any changes to your diabetes management. This podcast provides general information and discussions about health and related subjects. This information and other content provided in this podcast, or in any linked materials, are not intended and should not be construed as medical advice, nor is the information a substitute for professional medical expertise or treatment. If you or any other person has a medical concern, you should consult your health care provider or seek other professional medical treatment. Never disregard professional medical advice or delay in seeking it because of something that you have heard in this podcast or read in any linked materials. The opinions and views expressed on this podcast and website have no relation to those of any academic, hospital, health practice or other institution. 

**Please consult the Omnipod® 5 Automated Insulin Delivery System User Guide for more information.

]]> 1356 Omnipod® 5 Automated Insulin Delivery System: Facts vs. Fake News Part 1 Nancy Hanna RN, BSN, CDCES and Dena Gottesman MS, RD, CDCES are joined by Leslie Barrett MS, RD, CDCES to clear up common misconceptions about the Omnipod® 5 Automated Insulin Delivery System. Leslie has been working on Omnipod® 5 since the development from user experience and design to clinical trial site training and support. In this episode she will separate the facts from the fake news, share details on the Omnipod 5 algorithm known as SmartAdjust™ technology and best practices for everyday use and optimization. Questions covered in this episode:• How does the adaptivity of the system work?• What are the requirements for entering Automated Mode?• What should users expect during the first Pod wear?• What are the considerations for transitioning from different therapies?• How often should users deliver correction boluses?• What are the adjustable settings for Omnipod 5, and what does and does not impact algorithm behavior?  Please speak with your healthcare team before making any changes to your diabetes management. This podcast provides general information and discussions about health and related subjects. This information and other content provided in this podcast, or in any linked materials, are not intended and should not be construed as medical advice, nor is the information a substitute for professional medical expertise or treatment. If you or any other person has a medical concern, you should consult your health care provider or seek other professional medical treatment. Never disregard professional medical advice or delay in seeking it because of something that you have heard in this podcast or read in any linked materials. The opinions and views expressed on this podcast and website have no relation to those of any academic, hospital, health practice or other institution. **Please consult the Omnipod® 5 Automated Insulin Delivery System User Guide for more information. Thu, 15 Dec 2022 08:19:00 -0000 full Insulet, Maker of Omnipod Nancy Hanna RN, BSN, CDCES and Dena Gottesman MS, RD, CDCES are joined by Leslie Barrett MS, RD, CDCES to clear up common misconceptions about the Omnipod® 5 Automated Insulin Delivery System. Leslie has been working on Omnipod® 5 since the development from user experience and design to clinical trial site training and support. In this episode she will separate the facts from the fake news, share details on the Omnipod 5 algorithm known as SmartAdjust™ technology and best practices for everyday use and optimization. Questions covered in this episode:• How does the adaptivity of the system work?• What are the requirements for entering Automated Mode?• What should users expect during the first Pod wear?• What are the considerations for transitioning from different therapies?• How often should users deliver correction boluses?• What are the adjustable settings for Omnipod 5, and what does and does not impact algorithm behavior?  Please speak with your healthcare team before making any changes to your diabetes management. This podcast provides general information and discussions about health and related subjects. This information and other content provided in this podcast, or in any linked materials, are not intended and should not be construed as medical advice, nor is the information a substitute for professional medical expertise or treatment. If you or any other person has a medical concern, you should consult your health care provider or seek other professional medical treatment. Never disregard professional medical advice or delay in seeking it because of something that you have heard in this podcast or read in any linked materials. The opinions and views expressed on this podcast and website have no relation to those of any academic, hospital, health practice or other institution. **Please consult the Omnipod® 5 Automated Insulin Delivery System User Guide for more information.
Questions covered in this episode:

• How does the adaptivity of the system work?
• What are the requirements for entering Automated Mode?
• What should users expect during the first Pod wear?
• What are the considerations for transitioning from different therapies?
• How often should users deliver correction boluses?
• What are the adjustable settings for Omnipod 5, and what does and does not impact algorithm behavior?  

Please speak with your healthcare team before making any changes to your diabetes management. This podcast provides general information and discussions about health and related subjects. This information and other content provided in this podcast, or in any linked materials, are not intended and should not be construed as medical advice, nor is the information a substitute for professional medical expertise or treatment. If you or any other person has a medical concern, you should consult your health care provider or seek other professional medical treatment. Never disregard professional medical advice or delay in seeking it because of something that you have heard in this podcast or read in any linked materials. The opinions and views expressed on this podcast and website have no relation to those of any academic, hospital, health practice or other institution. 

**Please consult the Omnipod® 5 Automated Insulin Delivery System User Guide for more information.]]> 2328 Will Bolus for Beignets Part 2: Candid Conversations from ADA Synopsis: In the second part of this episode, Nancy and Dena continue with impromptu interviews of attendees at the 82nd ADA conference. These talks include topics such as the accessibility of new diabetes treatment technology with Dr. Osama Hamdy, helping patients achieve their diabetes goals with individualized care with Jeremy Beaulieu, glucose testing practices with Clinical Professor in Medicine Dr. Edward Chao, as well as a conversation with this year’s Outstanding Physician Clinician in Diabetes Award winner, Dr. Janet McGill. Guest Bios: Dr. Osama Hamdy, MD, is one of the world’s thought leaders in diabetes with over 40 years of experience in the field and a primary clinical interest in diabetes technology. Dr. Hamdy speaks to Nancy and Dena about the evolution of diabetes technology he has witnessed over the years and its tremendous impact on people with diabetes. Dr. Janet McGill is the Professor of Medicine at Washington University and this year’s Outstanding Physician Clinician in Diabetes award winner. She speaks to Nancy and Dena about her visions for the future of diabetes care and advice for young women in the industry. Dr. Edward Chao is a Clinical Professor of Medicine at the University of California with a particular passion for innovation and patient centered design. He speaks to Nancy and Dena about non-invasive glucose testing, design thinking, the user perspective and how it can be applied to improve patient care and help solve pain points. Jeremy Beaulieu is a Nurse Practitioner and CDCES with experience in both pediatric and adult diabetes. He speaks to Nancy and Dena about how unique journey to specializing in diabetes and an anecdote from a patient’s transformational journey to improved glycemia.  #Omnipod #DiabetesTechnology #AIDSystems #WomenInEndocrinology #PatientCare  Please speak with your Healthcare team before making any changes to your diabetes management.  This podcast provides general information and discussions about health and related subjects. This information and other content provided in this podcast, or in any linked materials, are not intended and should not be construed as medical advice, nor is the information a substitute for professional medical expertise or treatment. If you or any other person has a medical concern, you should consult your health care provider or seek other professional medical treatment. Never disregard professional medical advice or delay in seeking it because of something that you have heard in this podcast or read in any linked materials. The opinions and views expressed on this podcast and website have no relation to those of any academic, hospital, health practice or other institution.  **Please consult the Omnipod® 5 Automated Insulin Delivery System User Guide for more information.  Mon, 22 Aug 2022 13:15:00 -0000 full Insulet, Maker of Omnipod Synopsis: In the second part of this episode, Nancy and Dena continue with impromptu interviews of attendees at the 82nd ADA conference. These talks include topics such as the accessibility of new diabetes treatment technology with Dr. Osama Hamdy, helping patients achieve their diabetes goals with individualized care with Jeremy Beaulieu, glucose testing practices with Clinical Professor in Medicine Dr. Edward Chao, as well as a conversation with this year’s Outstanding Physician Clinician in Diabetes Award winner, Dr. Janet McGill. Guest Bios: Dr. Osama Hamdy, MD, is one of the world’s thought leaders in diabetes with over 40 years of experience in the field and a primary clinical interest in diabetes technology. Dr. Hamdy speaks to Nancy and Dena about the evolution of diabetes technology he has witnessed over the years and its tremendous impact on people with diabetes. Dr. Janet McGill is the Professor of Medicine at Washington University and this year’s Outstanding Physician Clinician in Diabetes award winner. She speaks to Nancy and Dena about her visions for the future of diabetes care and advice for young women in the industry. Dr. Edward Chao is a Clinical Professor of Medicine at the University of California with a particular passion for innovation and patient centered design. He speaks to Nancy and Dena about non-invasive glucose testing, design thinking, the user perspective and how it can be applied to improve patient care and help solve pain points. Jeremy Beaulieu is a Nurse Practitioner and CDCES with experience in both pediatric and adult diabetes. He speaks to Nancy and Dena about how unique journey to specializing in diabetes and an anecdote from a patient’s transformational journey to improved glycemia.  #Omnipod #DiabetesTechnology #AIDSystems #WomenInEndocrinology #PatientCare  Please speak with your Healthcare team before making any changes to your diabetes management.  This podcast provides general information and discussions about health and related subjects. This information and other content provided in this podcast, or in any linked materials, are not intended and should not be construed as medical advice, nor is the information a substitute for professional medical expertise or treatment. If you or any other person has a medical concern, you should consult your health care provider or seek other professional medical treatment. Never disregard professional medical advice or delay in seeking it because of something that you have heard in this podcast or read in any linked materials. The opinions and views expressed on this podcast and website have no relation to those of any academic, hospital, health practice or other institution.  **Please consult the Omnipod® 5 Automated Insulin Delivery System User Guide for more information. 
In the second part of this episode, Nancy and Dena continue with impromptu interviews of attendees at the 82nd ADA conference. 

These talks include topics such as the accessibility of new diabetes treatment technology with Dr. Osama Hamdy, helping patients achieve their diabetes goals with individualized care with Jeremy Beaulieu, glucose testing practices with Clinical Professor in Medicine Dr. Edward Chao, as well as a conversation with this year’s Outstanding Physician Clinician in Diabetes Award winner, Dr. Janet McGill. 

Guest Bios: 

Dr. Osama Hamdy, MD, is one of the world’s thought leaders in diabetes with over 40 years of experience in the field and a primary clinical interest in diabetes technology. Dr. Hamdy speaks to Nancy and Dena about the evolution of diabetes technology he has witnessed over the years and its tremendous impact on people with diabetes. 

Dr. Janet McGill is the Professor of Medicine at Washington University and this year’s Outstanding Physician Clinician in Diabetes award winner. She speaks to Nancy and Dena about her visions for the future of diabetes care and advice for young women in the industry. 

Dr. Edward Chao is a Clinical Professor of Medicine at the University of California with a particular passion for innovation and patient centered design. He speaks to Nancy and Dena about non-invasive glucose testing, design thinking, the user perspective and how it can be applied to improve patient care and help solve pain points. 

Jeremy Beaulieu is a Nurse Practitioner and CDCES with experience in both pediatric and adult diabetes. He speaks to Nancy and Dena about how unique journey to specializing in diabetes and an anecdote from a patient’s transformational journey to improved glycemia. 
 
#Omnipod #DiabetesTechnology #AIDSystems #WomenInEndocrinology #PatientCare 
 
Please speak with your Healthcare team before making any changes to your diabetes management.  
This podcast provides general information and discussions about health and related subjects. This information and other content provided in this podcast, or in any linked materials, are not intended and should not be construed as medical advice, nor is the information a substitute for professional medical expertise or treatment. If you or any other person has a medical concern, you should consult your health care provider or seek other professional medical treatment. Never disregard professional medical advice or delay in seeking it because of something that you have heard in this podcast or read in any linked materials. The opinions and views expressed on this podcast and website have no relation to those of any academic, hospital, health practice or other institution.  

**Please consult the Omnipod® 5 Automated Insulin Delivery System User Guide for more information. ]]> 1329 Will Bolus for Beignets Part 1: Candid Conversations from ADA Synopsis: In this episode, Nancy and Dena commence the first part of a compilation of interviews conducted at the 82nd ADA conference. These talks include topics such as exercise with closed-loop therapy with Dr. Laurel Messer, reducing stigma surrounding diabetes with Nicole Patience, and a conversation with this year’s Outstanding Educator in Diabetes Award winner, Dr. Amy-Hess Fischl.  Guest Bios: Dr. Laurel Messer, PhD, RN, CDCES is a Clinical Nurse Scientist and Assistant Professor at the Barbara Davis Center for Childhood Diabetes, University of Colorado. She is a research investigator in the pediatric artificial research program at the BDC and has been involved in over 100 clinical research trials of diabetes technology. She speaks to Nancy and Dena about using hybrid closed-loop AID systems for exercise management and the importance of customizable and individualized strategies.  Nicole Patience is an RD, CDCES,CEDRD, as well as an eating disorder specialist. She speaks to Nancy and Dena about the need for diabetes stigma education on every level from patient to practitioner and the benefits of plant-based eating.  Dr. Amy-Hess Fischl, RD, CDCES is this year’s recipient of the 2022 Outstanding Educator in Diabetes Award. She currently works at the University of Chicago Kovler Diabetes Center  and has a particular passion for working with adolescents. She speaks to Nancy and Dena about the importance of establishing a transition program into adulthood and the outreach and benefits of telemedicine.  #DiabetesTechnology #AIDSystems #Omnipod #HybridClosedLoop #DiabetesStigma #ExerciseManagement #Telemedicine Please speak with your Healthcare team before making any changes to your diabetes management.  This podcast provides general information and discussions about health and related subjects. This information and other content provided in this podcast, or in any linked materials, are not intended and should not be construed as medical advice, nor is the information a substitute for professional medical expertise or treatment. If you or any other person has a medical concern, you should consult your health care provider or seek other professional medical treatment. Never disregard professional medical advice or delay in seeking it because of something that you have heard in this podcast or read in any linked materials. The opinions and views expressed on this podcast and website have no relation to those of any academic, hospital, health practice or other institution.  **Please consult the Omnipod® 5 Automated Insulin Delivery System User Guide for more information. Mon, 22 Aug 2022 13:00:00 -0000 full Insulet, Maker of Omnipod Synopsis: In this episode, Nancy and Dena commence the first part of a compilation of interviews conducted at the 82nd ADA conference. These talks include topics such as exercise with closed-loop therapy with Dr. Laurel Messer, reducing stigma surrounding diabetes with Nicole Patience, and a conversation with this year’s Outstanding Educator in Diabetes Award winner, Dr. Amy-Hess Fischl.  Guest Bios: Dr. Laurel Messer, PhD, RN, CDCES is a Clinical Nurse Scientist and Assistant Professor at the Barbara Davis Center for Childhood Diabetes, University of Colorado. She is a research investigator in the pediatric artificial research program at the BDC and has been involved in over 100 clinical research trials of diabetes technology. She speaks to Nancy and Dena about using hybrid closed-loop AID systems for exercise management and the importance of customizable and individualized strategies.  Nicole Patience is an RD, CDCES,CEDRD, as well as an eating disorder specialist. She speaks to Nancy and Dena about the need for diabetes stigma education on every level from patient to practitioner and the benefits of plant-based eating.  Dr. Amy-Hess Fischl, RD, CDCES is this year’s recipient of the 2022 Outstanding Educator in Diabetes Award. She currently works at the University of Chicago Kovler Diabetes Center  and has a particular passion for working with adolescents. She speaks to Nancy and Dena about the importance of establishing a transition program into adulthood and the outreach and benefits of telemedicine.  #DiabetesTechnology #AIDSystems #Omnipod #HybridClosedLoop #DiabetesStigma #ExerciseManagement #Telemedicine Please speak with your Healthcare team before making any changes to your diabetes management.  This podcast provides general information and discussions about health and related subjects. This information and other content provided in this podcast, or in any linked materials, are not intended and should not be construed as medical advice, nor is the information a substitute for professional medical expertise or treatment. If you or any other person has a medical concern, you should consult your health care provider or seek other professional medical treatment. Never disregard professional medical advice or delay in seeking it because of something that you have heard in this podcast or read in any linked materials. The opinions and views expressed on this podcast and website have no relation to those of any academic, hospital, health practice or other institution.  **Please consult the Omnipod® 5 Automated Insulin Delivery System User Guide for more information.
In this episode, Nancy and Dena commence the first part of a compilation of interviews conducted at the 82nd ADA conference. 

These talks include topics such as exercise with closed-loop therapy with Dr. Laurel Messer, reducing stigma surrounding diabetes with Nicole Patience, and a conversation with this year’s Outstanding Educator in Diabetes Award winner, Dr. Amy-Hess Fischl. 
 
Guest Bios: 

Dr. Laurel Messer, PhD, RN, CDCES is a Clinical Nurse Scientist and Assistant Professor at the Barbara Davis Center for Childhood Diabetes, University of Colorado. She is a research investigator in the pediatric artificial research program at the BDC and has been involved in over 100 clinical research trials of diabetes technology. She speaks to Nancy and Dena about using hybrid closed-loop AID systems for exercise management and the importance of customizable and individualized strategies. 
 
Nicole Patience is an RD, CDCES,CEDRD, as well as an eating disorder specialist. She speaks to Nancy and Dena about the need for diabetes stigma education on every level from patient to practitioner and the benefits of plant-based eating. 
 
Dr. Amy-Hess Fischl, RD, CDCES is this year’s recipient of the 2022 Outstanding Educator in Diabetes Award. She currently works at the University of Chicago Kovler Diabetes Center  and has a particular passion for working with adolescents. She speaks to Nancy and Dena about the importance of establishing a transition program into adulthood and the outreach and benefits of telemedicine. 
 
#DiabetesTechnology #AIDSystems #Omnipod #HybridClosedLoop #DiabetesStigma #ExerciseManagement #Telemedicine 

Please speak with your Healthcare team before making any changes to your diabetes management.  
This podcast provides general information and discussions about health and related subjects. This information and other content provided in this podcast, or in any linked materials, are not intended and should not be construed as medical advice, nor is the information a substitute for professional medical expertise or treatment. If you or any other person has a medical concern, you should consult your health care provider or seek other professional medical treatment. Never disregard professional medical advice or delay in seeking it because of something that you have heard in this podcast or read in any linked materials. The opinions and views expressed on this podcast and website have no relation to those of any academic, hospital, health practice or other institution.  

**Please consult the Omnipod® 5 Automated Insulin Delivery System User Guide for more information.]]> 1181 Building Your Diabetes ​Dream Team Insulet has paid the guest speakers of this podcast, Dr. Gregory Forlenza and Dr. Diana Isaacs, a fee to participate in this podcast. Dr. Gregory Forlenza and Dr. Diana Isaacs have an ongoing commercial relationship with Insulet and receive financial compensation for this relationship.  Synopsis: In the second episode of Beyond the Bolus, Nancy and Dena examine the importance of the diabetes care team as they walk a day-in-the-life with Dr. Gregory Forlenza and Dr. Diana Isaacs. Over the episode, these experts discuss the value of a team approach within their practices, the benefits of shared medical appointments and telemedicine visits and practical tips for finding and utilizing a technology champion. Guest Bios: Dr. Gregory Forlenza, MD is a Pediatric Endocrinologist and Associate Professor at the Barbara Davis Center for Childhood Diabetes, University of Colorado, and his research is focused on technology to improve the health and lifestyle of people with type 1 diabetes. Dr. Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES is a Clinical Pharmacy Specialist and the Remote Monitoring Program Coordinator at the Cleveland Clinic Diabetes Center. Her primary clinical interests include medication management, diabetes education, running a robust CGM shared medical appointment program and insulin pump training. #DiabetesTechnology #CareTeam #Telemedicine #DayintheLife #PatientCare Please speak with your Healthcare team before making any changes to your diabetes management.  This podcast provides general information and discussions about health and related subjects. This information and other content provided in this podcast, or in any linked materials, are not intended and should not be construed as medical advice, nor is the information a substitute for professional medical expertise or treatment. If you or any other person has a medical concern, you should consult your health care provider or seek other professional medical treatment. Never disregard professional medical advice or delay in seeking it because of something that you have heard in this podcast or read in any linked materials. The opinions and views expressed on this podcast and website have no relation to those of any academic, hospital, health practice or other institution.  **Please consult the Omnipod® 5 Automated Insulin Delivery System User Guide for more information.  Mon, 22 Aug 2022 12:45:00 -0000 full Insulet, Maker of Omnipod Insulet has paid the guest speakers of this podcast, Dr. Gregory Forlenza and Dr. Diana Isaacs, a fee to participate in this podcast. Dr. Gregory Forlenza and Dr. Diana Isaacs have an ongoing commercial relationship with Insulet and receive financial compensation for this relationship.  Synopsis: In the second episode of Beyond the Bolus, Nancy and Dena examine the importance of the diabetes care team as they walk a day-in-the-life with Dr. Gregory Forlenza and Dr. Diana Isaacs. Over the episode, these experts discuss the value of a team approach within their practices, the benefits of shared medical appointments and telemedicine visits and practical tips for finding and utilizing a technology champion. Guest Bios: Dr. Gregory Forlenza, MD is a Pediatric Endocrinologist and Associate Professor at the Barbara Davis Center for Childhood Diabetes, University of Colorado, and his research is focused on technology to improve the health and lifestyle of people with type 1 diabetes. Dr. Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES is a Clinical Pharmacy Specialist and the Remote Monitoring Program Coordinator at the Cleveland Clinic Diabetes Center. Her primary clinical interests include medication management, diabetes education, running a robust CGM shared medical appointment program and insulin pump training. #DiabetesTechnology #CareTeam #Telemedicine #DayintheLife #PatientCare Please speak with your Healthcare team before making any changes to your diabetes management.  This podcast provides general information and discussions about health and related subjects. This information and other content provided in this podcast, or in any linked materials, are not intended and should not be construed as medical advice, nor is the information a substitute for professional medical expertise or treatment. If you or any other person has a medical concern, you should consult your health care provider or seek other professional medical treatment. Never disregard professional medical advice or delay in seeking it because of something that you have heard in this podcast or read in any linked materials. The opinions and views expressed on this podcast and website have no relation to those of any academic, hospital, health practice or other institution.  **Please consult the Omnipod® 5 Automated Insulin Delivery System User Guide for more information. 
Synopsis: 

In the second episode of Beyond the Bolus, Nancy and Dena examine the importance of the diabetes care team as they walk a day-in-the-life with Dr. Gregory Forlenza and Dr. Diana Isaacs. 
Over the episode, these experts discuss the value of a team approach within their practices, the benefits of shared medical appointments and telemedicine visits and practical tips for finding and utilizing a technology champion. 

Guest Bios: 

Dr. Gregory Forlenza, MD is a Pediatric Endocrinologist and Associate Professor at the Barbara Davis Center for Childhood Diabetes, University of Colorado, and his research is focused on technology to improve the health and lifestyle of people with type 1 diabetes. 

Dr. Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES is a Clinical Pharmacy Specialist and the Remote Monitoring Program Coordinator at the Cleveland Clinic Diabetes Center. Her primary clinical interests include medication management, diabetes education, running a robust CGM shared medical appointment program and insulin pump training.
 
#DiabetesTechnology #CareTeam #Telemedicine #DayintheLife #PatientCare 

Please speak with your Healthcare team before making any changes to your diabetes management.  
This podcast provides general information and discussions about health and related subjects. This information and other content provided in this podcast, or in any linked materials, are not intended and should not be construed as medical advice, nor is the information a substitute for professional medical expertise or treatment. If you or any other person has a medical concern, you should consult your health care provider or seek other professional medical treatment. Never disregard professional medical advice or delay in seeking it because of something that you have heard in this podcast or read in any linked materials. The opinions and views expressed on this podcast and website have no relation to those of any academic, hospital, health practice or other institution.  

**Please consult the Omnipod® 5 Automated Insulin Delivery System User Guide for more information. ]]> 2306 The Future is Bright - Clinical Data and New Technology Insulet has paid the guest speakers of this podcast, Dr. Grazia Aleppo and Dr. Amy Criego, a fee to participate in the making of this podcast. Dr. Grazia Aleppo and Dr. Amy Criego have an ongoing commercial relationship with Insulet and receive financial compensation for this relationship.  Synopsis: In the inaugural episode of Beyond the Bolus, recorded live from the 82nd American Diabetes Association Conference, Nancy and Dena meet with Endocrinologists Dr. Grazia Aleppo and Dr. Amy Criego to discuss ADA highlights and understand how technology advancements are translating into day-to-day wins for people with diabetes. They discuss NEW extension data from the Omnipod 5 Automated Insulin Delivery System and their clinical pearls and real-world experience with Omnipod 5 during the pivotal trial and extension. They share the challenges and wins for both the adult and pediatric populations and the tremendous impact that technology can have in simplifying life for people with diabetes. Guest Bios: Dr. Grazia Aleppo, MD is an Endocrinologist at Northwestern Memorial Hospital in Chicago, IL. Her primary clinical interest is exploring diabetes technology, particularly the application of insulin pump therapy and real-time CGM sensor therapy and has contributed to over 70 publications and medical journals. Dr. Amy Criego, MD is an established Pediatric Endocrinologist and Medical Director at the Park Nicollet International Diabetes Center, involved in programming and clinical research. Having lived with T1D herself, she appreciates a team approach to diabetes care and management to allow patients and families flexible and active lives while maintaining good control. #Omnipod #ClinicalData #AIDSystems #DiabetesTechnology #82ndADA Please speak with your Healthcare team before making any changes to your diabetes management.  This podcast provides general information and discussions about health and related subjects. This information and other content provided in this podcast, or in any linked materials, are not intended and should not be construed as medical advice, nor is the information a substitute for professional medical expertise or treatment. If you or any other person has a medical concern, you should consult your health care provider or seek other professional medical treatment. Never disregard professional medical advice or delay in seeking it because of something that you have heard in this podcast or read in any linked materials. The opinions and views expressed on this podcast and website have no relation to those of any academic, hospital, health practice or other institution.  **Please consult the Omnipod® 5 Automated Insulin Delivery System User Guide for more information.  Mon, 22 Aug 2022 12:30:00 -0000 full Insulet, Maker of Omnipod Insulet has paid the guest speakers of this podcast, Dr. Grazia Aleppo and Dr. Amy Criego, a fee to participate in the making of this podcast. Dr. Grazia Aleppo and Dr. Amy Criego have an ongoing commercial relationship with Insulet and receive financial compensation for this relationship.  Synopsis: In the inaugural episode of Beyond the Bolus, recorded live from the 82nd American Diabetes Association Conference, Nancy and Dena meet with Endocrinologists Dr. Grazia Aleppo and Dr. Amy Criego to discuss ADA highlights and understand how technology advancements are translating into day-to-day wins for people with diabetes. They discuss NEW extension data from the Omnipod 5 Automated Insulin Delivery System and their clinical pearls and real-world experience with Omnipod 5 during the pivotal trial and extension. They share the challenges and wins for both the adult and pediatric populations and the tremendous impact that technology can have in simplifying life for people with diabetes. Guest Bios: Dr. Grazia Aleppo, MD is an Endocrinologist at Northwestern Memorial Hospital in Chicago, IL. Her primary clinical interest is exploring diabetes technology, particularly the application of insulin pump therapy and real-time CGM sensor therapy and has contributed to over 70 publications and medical journals. Dr. Amy Criego, MD is an established Pediatric Endocrinologist and Medical Director at the Park Nicollet International Diabetes Center, involved in programming and clinical research. Having lived with T1D herself, she appreciates a team approach to diabetes care and management to allow patients and families flexible and active lives while maintaining good control. #Omnipod #ClinicalData #AIDSystems #DiabetesTechnology #82ndADA Please speak with your Healthcare team before making any changes to your diabetes management.  This podcast provides general information and discussions about health and related subjects. This information and other content provided in this podcast, or in any linked materials, are not intended and should not be construed as medical advice, nor is the information a substitute for professional medical expertise or treatment. If you or any other person has a medical concern, you should consult your health care provider or seek other professional medical treatment. Never disregard professional medical advice or delay in seeking it because of something that you have heard in this podcast or read in any linked materials. The opinions and views expressed on this podcast and website have no relation to those of any academic, hospital, health practice or other institution.  **Please consult the Omnipod® 5 Automated Insulin Delivery System User Guide for more information.   
Synopsis: 

In the inaugural episode of Beyond the Bolus, recorded live from the 82nd American Diabetes Association Conference, Nancy and Dena meet with Endocrinologists Dr. Grazia Aleppo and Dr. Amy Criego to discuss ADA highlights and understand how technology advancements are translating into day-to-day wins for people with diabetes. 

They discuss NEW extension data from the Omnipod 5 Automated Insulin Delivery System and their clinical pearls and real-world experience with Omnipod 5 during the pivotal trial and extension. 
They share the challenges and wins for both the adult and pediatric populations and the tremendous impact that technology can have in simplifying life for people with diabetes. 

Guest Bios: 

Dr. Grazia Aleppo, MD is an Endocrinologist at Northwestern Memorial Hospital in Chicago, IL. Her primary clinical interest is exploring diabetes technology, particularly the application of insulin pump therapy and real-time CGM sensor therapy and has contributed to over 70 publications and medical journals. 

Dr. Amy Criego, MD is an established Pediatric Endocrinologist and Medical Director at the Park Nicollet International Diabetes Center, involved in programming and clinical research. Having lived with T1D herself, she appreciates a team approach to diabetes care and management to allow patients and families flexible and active lives while maintaining good control. 

#Omnipod #ClinicalData #AIDSystems #DiabetesTechnology #82ndADA 

Please speak with your Healthcare team before making any changes to your diabetes management.  
This podcast provides general information and discussions about health and related subjects. This information and other content provided in this podcast, or in any linked materials, are not intended and should not be construed as medical advice, nor is the information a substitute for professional medical expertise or treatment. If you or any other person has a medical concern, you should consult your health care provider or seek other professional medical treatment. Never disregard professional medical advice or delay in seeking it because of something that you have heard in this podcast or read in any linked materials. The opinions and views expressed on this podcast and website have no relation to those of any academic, hospital, health practice or other institution. 
 
**Please consult the Omnipod® 5 Automated Insulin Delivery System User Guide for more information. 

]]> 1883 Welcome to Beyond The Bolus Find out more about what you can expect from this debut podcast series from Insulet including the first episodes recorded live at ADA in New Orleans in June. Tue, 31 May 2022 15:54:00 -0000 trailer Insulet, Maker of Omnipod Find out more about what you can expect from this debut podcast series from Insulet including the first episodes recorded live at ADA in New Orleans in June. 70